

MEMORANDUM

TO: Mayor Philip Levine and Members of the City Commission

FROM: Rafael E. Granado, City Clerk

DATE: February 9, 2014

SUBJECT: City Commission At-Large Nominations for February 10, 2016, – Release # 5

Below please find the City Commission At-Large Nominations received to date for the February 10, 2016 Commission Meeting. Changes made since Release # 4, are shown in red.

BOARD AND COMMITTEES

1. AFFORDABLE HOUSING ADVISORY COMMITTEE VACANCIES (6):

- **Beth B. Butler** (Release # 1, Page 5)
 - Nominated for **appointment** (citizen who represents employers within the jurisdiction) by Commissioner Grieco. (Release # 3, Page 1 - category change)

- **Janie P. Hayes** (Release # 1, Page 13)
 - Nominated for **appointment** (citizen actively engaged as an advocate for low-income persons in connection with affordable housing) by Commissioner Rosen Gonzalez.

- **Francis (Frankie) Trullenque** (Release # 1, Page 21)
 - Nominated for **appointment** (citizen actively engaged as an advocate for low-income persons in connection with affordable housing) by Vice-Mayor Alemán.
 - Nominated for **appointment** (citizen actively engaged as an advocate for low-income persons in connection with affordable housing) by Commissioner Malakoff. (Release # 2, Page 1)
 - Nominated for **appointment** (citizen actively engaged as an advocate for low-income persons in connection with affordable housing) by Mayor Levine. (Release # 3, Page 1)

 - Nominated for **appointment** (citizen actively engaged as an advocate for low-income persons in connection with affordable housing) by Commissioner Arriola. (Release # 3, Page 1)

- **Jeffrey M. Feldman**
 - Nominated for **appointment** (citizen who actively serves on the local planning agency pursuant to F.S. § 163.3174 [Planning Board Member]) by Commissioner Grieco. (Release # 4, Page 5)

2. BUDGET ADVISORY COMMITTEE VACANCY (1):

No nomination received do date.

3. HEALTH ADVISORY COMMITTEE VACANCIES (3):

- **Dr. Todd M. Narson** (Release # 1, Page 29)
 - Nominated for **reappointment** (health benefits provider) by Commissioner Malakoff.
 - Nominated for **reappointment** (health benefits provider) by Vice-Mayor Alemán. (Release # 2, Page 1)

- **Dr. Richard M. Awdeh** (Release # 5, Page 5)
 - Nominated for **reappointment** (corporate individual) by Commissioner Malakoff.

- **Dr. Anthony J. Japour** (Release # 5, Page 17)
 - Nominated for **reappointment** (administrator from an ACLF/ALF) by Commissioner Malakoff.

4. MIAMI BEACH HUMAN RIGHTS COMMITTEE VACANCY (1):

- **Clare F. McCord** (Release # 1, Page 47)
 - Nominated for **appointment** by Vice-Mayor Alemán.
 - Nominated for **appointment** by Commissioner Arriola.
 - Nominated for **appointment** by Commissioner Malakoff.
 - Nominated for **appointment** by Commissioner Rosen Gonzalez.
 - Nominated for **appointment** by Commissioner Grieco. (Release # 2, Page 1)

Dr. Richard M. Awdeh

THIS PAGE INTENTIONALLY LEFT BLANK



NAME: Awdeh Richard
 Last Name First Name Middle Initial

HOME ADDRESS: Miami Beach FL 33139
 Apt No. Home No./Street City State Zip Code

PHONE: _____ richard.awdeh@gmail.com
 Home Work Email Address

Business Name: Bascom Palmer Eye Institute Position: Physician

Address: 900 NW 17th Street Miami FL 33136
 Street City State Zip Code

Pursuant to City Code section 2-22(4) a and b: Members of agencies, boards, and committees shall be affiliated with the city; this requirement shall be fulfilled in the following ways: a) an individual shall have been a resident of the city for a minimum of six months; or b) an individual shall demonstrate ownership/interest for a minimum of six months in a business established in the city.

- Resident of Miami Beach for a minimum of six (6) months: **Yes**
- Demonstrate an ownership/interest in a business in Miami Beach for a minimum of six (6) months: **No**
- Are you a registered voter in Miami Beach: **Yes**
- (Please circle one): I am now a resident of: **South Beach**
- I am applying for an appointment because I have special abilities, knowledge and experience. Please list below:
I am a physician in Miami.
- Are you presently a registered lobbyist with the City of Miami Beach? **No**

Please list your preferences in order of ranking [1] first choice [2] second choice, and [3] third choice. **Please note that only three (3) choices will be observed by the City Clerk's Office.** (Regular Boards of City)

Choice 1: Health Advisory Committee

Choice 2:

Choice 3:

Note: If applying for Youth Advisory Board, please indicate your affiliation with the Scott Rakow Youth Center: _____

1. Past service on the Youth Center Advisory Board: **No** Years of Service: _____
2. Present participation in Youth Center activities by your children **No** if yes, please list the names of your children, their ages, and which programs. List below:

- Have you ever been convicted of a felony: **No** If yes, please explain in detail: _____
- Do you currently have a violation(s) of City of Miami Beach codes: **No** If yes, please explain in detail: _____
- Do you currently owe the City of Miami Beach any money: **No** If yes, please explain in detail: _____
- Are you currently serving on any City Boards or Committees: **No** If yes, which board? _____
- What organizations in the City of Miami Beach do you currently hold membership in? _____
- List all properties owned or have an interest in, which are located within the City of Miami Beach: _____
- I am now employed by the city of Miami Beach: **No** Which department? _____

The following information is voluntary and is not a part of your application nor has any bearing on your consideration for appointment. It is being asked to comply with federal equal opportunity reporting requirements.

Gender: Male

Race/Ethnic Categories

What is your race? Mark one or more races to indicate what you consider yourself to be. **White**

Other Description:

Are you Spanish/Hispanic/ Latino? Mark the "No" box if not Spanish / Hispanic / Latino. **No**

Physically Challenged: **No**

NOTE: If appointed, you will be required to follow certain laws which apply to city board/committee members. These laws include, but are not limited to, the following:

- o Prohibition from directly or indirectly lobbying city personnel (Miami Beach City Code section 2-459).
- o Prohibition from contracting with the city (Miami-Dade County Code section 2-11.1).
- o Prohibition from lobbying before board/committee you have served on for period of one year after leaving office (Miami Beach Code section 2-26).
- o Requirement to disclose certain financial interests and gifts (Miami-Dade County Code section 2-11.1).
(re: CMB Community Development Advisory Committee): prohibition, during tenure and for one year after leaving office, from having any interest in or receiving any benefit from Community Development Block Grant funds for either yourself, or those with whom you have business or immediate family ties (CFR 570.611).

Upon request, copies of these laws may be obtained from the City Clerk.

"I hereby attest to the accuracy and truthfulness of the application and have received, read and will abide by Chapter 2, Article VII – of the City Code "Standards of Conduct for City Officers, Employees and Agency Members."

I Richard Awdeh agreed to the following terms on

Received in the City Clerk's Office by:

Name of Deputy Clerk

Control No.

Date

Richard M. Awdeh, M.D.

DIRECT: (b) (6) • E-MAIL (b) (6)

CURRENT POSITION:

United States, Food and Drug Administration Washington, DC
Chairman, Dermatologic and Ophthalmic Drugs Advisory Committee Jan 2015 – Jan 2019

Circle Miami, Florida
Founder, Chief Executive Officer Nov 2011 – Present

CheckedUp New York, NY
Founder, Chief Executive Officer Dec 2012 – Present

Bascom Palmer Eye Institute, University of Miami Miami, Florida
Assistant Professor of Ophthalmology July 2009 – Present
Assistant Professor of Pathology
Assistant Professor of Molecular Biology and Biochemistry
Executive Medicine, Ophthalmology

Director, Technology Transfer in Ophthalmology July 2009 – July
2012

Team Ophthalmologist, University of Miami Hurricanes
Team Ophthalmologist, Miami Marlins

MEDICAL TRAINING:

Bascom Palmer Eye Institute Miami, Florida
Fellow, Cornea and Refractive Surgery July 2008 – July 2009
• Post Graduate Year – V Fellowship Training

Duke University, Department of Ophthalmology Durham, North Carolina
Resident, Ophthalmology July 2005 – June 2008
• Post Graduate Year – II - IV Residency Training
• Winner Duke Ocular Innovation Award

Memorial Sloan-Kettering Cancer Center New York, New York
Internship, Internal Medicine June 2004 – June 2005
• Post Graduate Year – I Residency Training

EDUCATION:

Yale University, School of Medicine New Haven, Connecticut
Doctor of Medicine August 2000 - May 2004

- Board Certified, United States Medical Licensing Exam (USMLE) Step 1, Step 2 & Step 3
- Medical School Thesis Project: Treatment of Optic Pathway Gliomas (Honors)
- President, American Medical Association, Student Chapter, Yale University
- Yale Student Research Grant Recipient – Summer 2001, Spring 2003

Emory University Atlanta, Georgia
Goizueta Business School August 1995 – May 1999

- Valedictorian of Emory Business School
- Summa Cum Laude, Highest Honors
- Commencement speaker

London School of Economics, July 1997 London, England

- International Business Strategy Course concentrating on topics of European Monetary Union, routes for achieving international expansion, and managing a multi-national corporation.

Harvard University Graduate School of Business

Summer Venture in Management Program, June 1998

Boston, Massachusetts

- Focused on entrepreneurial management and the dynamics of teams in today's work environment.

RESEARCH FUNDING:

National Institutes of Health / National Eye Institute

Molecular in vivo imaging of ophthalmic tumors

R21 EY020940-01

2012

September 2010 – September

(b) (4)

Carl Zeiss AG Research Grant

2008

Research to Prevent Blindness Resident Support

2008

2005-

Yale School of Medicine Student Research Grant

2003

Summer

Yale School of Medicine Student Research Grant

2001

Summer

HEALTH RELATED EXPERIENCE:

2008 Paul Kayser International Scholar

Buenos Aires, Argentina

Awarded by the Pan-American Association of Ophthalmology, December 2007

United States Food and Drug Administration

Center for Drug Evaluation and Research – Resident Medical Officer, Summer 2007

- Acted in the capacity of a Medical Officer (MO) in a multi-disciplinary team including pharmacologists, microbiologists, chemists, statisticians, compliance officers and physicians in the evaluation of new ophthalmic drugs.
- Critically analyzed Investigational New Drug (IND) and New Drug Application (NDA) clinical trial design and statistical methods for Phase I, II, and III trials.
- Participated in industry conference calls and meetings regarding clinical trial design, methods, and results.
- Completed courses in clinical trial design and statistical methods.

Yale MD Thesis Project / St. Jude's Children Research Hospital

Clinical Researcher

- *See description above.*

Bascom Palmer Eye Institute, University of Miami

Visiting Resident, Orbital Oncology/Oculoplastics Service, November 2004

Doheny Eye Institute, University of Southern California

Visiting Medical Student / Researcher, Summer 2003

- Contributed to several clinical research projects in ophthalmology including the Intraocular Retinal Prosthesis

Project, 25-Gauge Sutureless Vitrectomy Surgery, and patient Quality of Life following retinal surgery.

Emory University School of Medicine

Basic Science Researcher, August 1999 – May 2000

- Conducted research on Nuclear Pore Complex, specifically studying the role of protein NUP 98 in transport both into and out of nucleus in a Xenopus system. Gained basic science bench skills including running Western Blots, polyacrylamide gels, Polymerase Chain Reaction (PCR), protein affinity columns, and protein assays.

PRIOR WORK EXPERIENCE:

Arthur Andersen, LLP.

Summer Analyst, Summer 1998

Goldman, Sachs & Co.

Research Analyst, Fall 1997

Summer Analyst, Summer 1997

PROFESSIONAL SOCIETIES:

- American Board of Ophthalmology (ABO), Diplomate
- American College of Ophthalmic Surgeons (ACOS), 2010 – Present (Founding Member)
- American Academy of Ophthalmology (AAO), 2005-Present
- Corneal External Disease and Refractive Surgeons (CEDARS), 2012 – Present (Founding Member)
- Association for Research in Vision and Ophthalmology (ARVO), 2003-Present
- American Medical Association, 2000-Present
- American Society of Cataract and Refractive Surgeons (ASCRS) and American Society of Ophthalmic Administrators, 2005-Present
- Sports Ophthalmology Society of the Americas, Founding Board, 2005-Present
- North Carolina Medical Society, Member
- North Carolina Ophthalmology Society, Member

RESEARCH:

Courses Taught:

Awdeh RM, Donnenfeld E, Slade S, Dell S, Culberston W, Krueger, R, Trattler, W, Kilic, A. Femtosecond laser cataract surgery. American Society of Cataract and Refractive Surgeons. Boston, MA, October, 2014.

Dunbar M, **Awdeh, RM.** Breaking News from Bascom Palmer. SECO, New Orleans, LA, March 2014.

Awdeh RM, Trattler, W, Donnenfeld, E. Digital Tools for Patient Education and Communication. American Society of Ophthalmic Administrators. Boston, MA, October, 2014.

Awdeh RM, Donnenfeld E, Slade S, Dell S, Culberston W, Krueger, R, Trattler, W, Kilic, A. Femtosecond laser cataract surgery. American Society of Cataract and Refractive Surgeons. San Francisco, CA, April 2013

Awdeh RM, Slade S, Dell S, Trattler W, Culbertson W, Nichamin S. Femtosecond laser cataract surgery. American Academy of Ophthalmology. Orlando, FL, October, 2011.

Awdeh RM, Slade S, Dell S, Trattler W, Culbertson W, Nichamin S. Femtosecond laser cataract surgery. American Society of Cataract and Refractive Surgeons. San Diego, CA, March 27, 2011.

Toyos R, O'Brien TP, Seiller B, **Awdeh RM, Trattler H.** Vision and Sports: Sports Ophthalmology Society of the Americas. American Society of Cataract and Refractive Surgeons. Chicago, IL, April 7, 2008.

Toyos R, Kim T, O'Brien TP, Mah FS, Schuler W, **Awdeh RM, Trattler WB.** Vision and Sports: Sports Ophthalmology Society of the Americas. American Society of Cataract and Refractive Surgeons. San Diego, CA, May 1, 2007.

Biomedical Engineering: Design in Biotechnology, Duke University, Spring 2006 – Teacher’s Assistant
Led a team of engineering students in the design and development of a novel device for intraocular pressure measurements.

Yale School of Medicine Thesis:

Awdeh RM. Visual Outcome using Conformal Radiation Therapy versus Chemotherapy versus Surgery in the treatment of Optic Pathway Gliomas.

Book Chapters:

Awdeh RM, Lakhnpal RR, Humayun MS. “Artificial Vision, Visual Prostheses & Retinal Implants” in Tano Y, Alfaro DV, Liggett PE, Mieler WF, Quiroz-Mercado H, Jager RD ed. Age-related Macular Degeneration: A Comprehensive Textbook. Lippincott, Williams & Wilkins. October 1, 2005.

(b) (4)

Peer-Reviewed Scientific Papers:

de la Zerda, A, Prabhulkar, S, Perez, VL, Ruggeri, M, Paranjape, AS, Habte, F, Gambhir, SS, **Awdeh, RM.** Optical Coherence contrast imaging using gold nanorods in living mice. *Clinical and Experimental Ophthalmology*, 2014.

Awdeh, RM, Kiehna, EN, Drewry, RD, Kerr, NC, Haik, BG, Wu, S, Xiong, X, Merchant, TE. Visual Outcomes in Pediatric Optic Pathway Glioma after Conformal Radiation Therapy. *International Journal of Radiation Oncology*, 2012, 84(1). 46-51.

Prabhulkar S, Matthews J, Rawal S, **Awdeh RM.** Molecular Histopathology Using Gold Nanorods and Optical Coherence Tomography. *Investigative Ophthalmology & Visual Science*, 2013, 54(2), 1192-1200.

Prabhulkar S, de la Zerda A, Paranjape A, **Awdeh RM.** Single Step Nanoplasmonic Immunoassay for the measurement of protein biomarkers. *Biosensors*. 2013, 3(1), 77-88.

Awdeh RM, Vroman DT, Ying MS, Goldman D, Kymionis G, Yoo SH. Phototherapeutic keratectomy for treatment of subepithelial fibrosis and anterior corneal scarring following Descemet’s stripping automated endothelial keratoplasty. *Cornea*. 2012 July, 31(7), 761–763.

Trattler WB, **Awdeh RM,** Albe E. The Ballots Are in. The all-time most-viewed videos on Eyetube.net. *Cataract & Refractive Surgery Today*. February 2011. Pages 19-20.

Awdeh, RM, Alfonso, E, Humayun MS. Ophthalmic Innovation: The eyes have it. *Medical Innovation and Business*. 2(1):10-14, Spring 2010. (Featured, Cover Article)

Awdeh RM, Trattler WB, It’s All in the Details. Exploring the fine points on Eyetube net. *Cataract & Refractive Surgery Today*. September 2010. Pages 25-26.

Awdeh, RM, Alfonso, E, Humayun MS. Ophthalmic Innovation and the Venture Capital Space. *Cataract and Refractive Surgery Today: Innovation 2010*. January, 2010. (Featured Article to Book)

Awdeh RM, Galchus S, Deramo V, Stinnett S, Lee P, Fekrat S. Vision-related quality of life in persons with branch retinal vein occlusion (BRVO) using the 25-Item NEI Visual Function Questionnaire. *Br J Ophthalmol*. 2010 Mar 94 (3).

Awdeh RM, Boggiano C, Goldberg DF, Starr CE, Stein J. What Type of Practice Does One Choose? Physicians and an employment specialist discuss career options. *Cataract & Refractive Surgery Today*. November 2009. Pages 40-45.

Awdeh RM, Koreishi AF. Are donor corneoscleral rim cultures in penetrating keratoplasty clinically relevant? *American Academy of Ophthalmology Current Insight*. Q3, July 23, 2008.

Awdeh RM, DeStefano JJ, Blackmon DM, Cummings TJ, Kim T. The Presence of T-lymphocyte Subpopulations (CD4 and CD8) in Pterygia: Evaluation of the Inflammatory Response. *Adv Ther* 2008 Sep-Oct; 25(5):479-87.

Awdeh RM, Galchus S, Deramo V, Stinnett S, Lee P, Fekrat S. Vision-related quality of life in persons with branch retinal vein occlusion (BRVO) using the 25-Item NEI Visual Function Questionnaire. *Accepted to British Journal of Ophthalmology*. 2010 Mar 94 (3).

(b) (4)

Abstracts / Presentations:

Awdeh RM. Digital Management and Education of Cataract Patients: Analyzing Effects of a Mobile Health Platform. American Academy of Ophthalmology, Chicago, IL, October 2014.

Awdeh RM. Hanrahan, D, Yoo, S, Katz, J, Donnenfeld, E, Ingrosso M. Digital Management and Education of Cataract Patients: Analyzing Effects of a Mobile Health Platform. American Society of Cataract and Refractive Surgery, Boston, MA, April 2014.

Awdeh RM. Surgical Guidance System. American Society of Cataract and Refractive Surgery, Boston, MA, April 2014.

Awdeh RM, Prabhulkar S, de la Zerda A, Gambhir S. Development Of Functionalized Gold Nanoparticles As Diagnostic And Therapeutic Agents For Age-Related Macular Degeneration. ARVO, Fort Lauderdale, FL, May 2012.

Matthews JL, Prabhulkar S, de la Zerda A, Gambhir S, Awdeh RM. Tumors and Non-neoplastic Lesions: Expanding Frontiers from Histology to Molecular Histopathology and Gene Expression. ARVO, Fort Lauderdale, FL, May 2012.

Prabhulkar S, de la Zerda A, Gambhir S, Awdeh RM. Development Of Single Step Nano-Optical Immunoassay As A Replacement For ELISA For The Measurement of Protein Biomarkers Upregulated in Disease State. ARVO, Fort Lauderdale, FL, May 2012.

Awdeh RM, de la Zerda A, Perez VL, Rugerri M, Gambhir S. Optical Coherence Molecular Imaging Using Gold Nanorods In Living Mice Eyes. ARVO, Fort Lauderdale, FL, May 2011.

Awdeh RM, Yoo SH, Culbertson WW. Femtosecond lasers to create astigmatic keratotomies. Association for Research in Vision and Ophthalmology, Surface Ablation, Femtolasers, and Crosslinking Conference. Fort Lauderdale, FL, May 2010.

Awdeh RM, Yoo SH. Confocal microscopy for the detection of acanthamoeba cysts. American Society of Cataract and Refractive Surgeons. Dimitri Azar Conference. Boston, MA, April 2010.

Lora A, Karp C, Vedula A, Yoo SH, Culbertson WW, Awdeh RM. Post LASIK Peripheral Inflammatory Keratitis. American Society of Cataract and Refractive Surgeons. Boston, MA, April 2010.

Vedula A, Awdeh RM, Goldman DA. Permanent Tattoo of a Descemet Stripping Endothelial Keratoplasty Button. American Society of Cataract and Refractive Surgeons. Boston, MA, April 2010.

- Awdeh RM.** Surgical Management of the Mature Cataract. Cataract and Refractive Surgery Congress. Miami, FL, February 2010.
- Awdeh RM.** Metallic nanoparticles as anti-infective agents. International Congress on Ocular Infection. Palm Beach, FL, February 2010.
- Awdeh RM.** Ocular Allergy Presentation; Executive Board of ISTA Pharmaceuticals. January 2010.
- Awdeh RM.** Bascom Palmer Eye Innovations: A Portfolio of Technology for the Future of Ophthalmology. University of Miami, Innovation Technology Showcase. Miami, FL, November, 2009.
- Awdeh RM.** Dry eye and the patient with cataract. American Society of Ophthalmic Registered Nurses Conference. Miami, FL, September 2009.
- Awdeh RM, Chang VS, Ide T, Culbertson WW, Yoo SH.** Laser in Situ Keratomileusis Using the VisuMax-MEL80 Platform for Correction of Myopia: Preliminary Report. American Society of Cornea and Refractive Surgeons. San Francisco, CA, April 2009.
- Awdeh RM, Galchus S, Deramo V, Stinnett S, Lee P, Fekrat S.** Vision-related quality of life in persons with branch retinal vein occlusion (BRVO) using the 25-Item NEI Visual Function Questionnaire.. *(Paper)* Duke Residents and Fellows Day, June 2008.
- Awdeh RM, Kim TK.** Sutureless Lamellar Keratoplasty: New Technique of Tisseel Glue Application. American Society of Cornea and Refractive Surgeons. Chicago, IL, April, 2008.
- Awdeh RM, Koreishi A, Davies E, Stopa M, Bower B, Izatt JA, Toth C.** High-Speed, High-Resolution Spectral Domain OCT Improves Imaging, Localization, and Quantification of Macular Pathology in AMD. *(Paper)* Duke Residents and Fellows Day, June 2007.
- Awdeh RM, Koreishi A, Davies E, Stopa M, Bower B, Izatt JA, Toth C.** High-Speed, High-Resolution Spectral Domain OCT Improves Imaging, Localization, and Quantification of Macular Pathology in AMD. *(Poster)* Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL. May 8, 2007.
- Ahmadi M, Awdeh RM, Adelman, RA.** Quality of Life Study Comparing Pneumatic Retinopexy to Scleral Buckle for the Treatment of Retinal Detachment. (Update) *(Poster)* Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL. May 10, 2007.
- Awdeh RM, Carlson AL.** Slit Lamp Technique for the Repositioning of Dislocated DSEK Grafts. American Society of Cornea and Refractive Surgeons. San Diego, CA, May 2, 2007.
- Awdeh RM, Freedman S, Kim T.** A New Treatment for Corneal Intrastromal Epithelial Cysts. *(Paper)* Cornea and Refractive Surgery Congress, Bascom Palmer Eye Institute. Miami, FL. February 9, 2007.
- Awdeh RM, Davies E, Koreishi A, Stopa M, Bower BA, Izatt JA, Toth CA.** Spectral Domain OCT Improves Imaging and Localization of Macular Pathology in AMD. *(Poster)* American Academy of Ophthalmology. Las Vegas, NV. November 13, 2007.
- **Winner:** Best Poster.
- Awdeh RM, Carlson AL.** Verisyse Phakic Refractive IOL: Outcomes and Complications. *(Poster)* presented at the annual meeting of The American Society of Cornea and Refractive Surgeons. San Francisco, CA. May 2006.
- Awdeh RM, Carlson AL.** Verisyse Phakic Refractive IOL: Outcomes and Complications. *(Paper)* presented at the annual meeting of The American Society of Cornea and Refractive Surgeons. San Francisco, CA, May 2006.
- **Winner:** Paper of Interest.
- Awdeh RM, Suner I.** The Role of Peripheral Retinal Nonperfusion in the Progression of Diabetic Eye Disease: An

Evaluation of Ultrawidefield Digital Angiography. (*Paper*) Duke, University of North Carolina, Wake Forest Annual Retina Conference. Winston Salem, NC. November 5, 2005.

Awdeh RM, Vedula AS, Membreno JH, Awdeh MM, Adelman RA. A Quality of Life Study Comparing Scleral Buckle to Pneumatic Retinopexy for the Treatment of Retinal Detachment. (*Poster*) Association for Research in Vision and Ophthalmology. Fort Lauderdale, FL. May 2004.

Awdeh RM, Drewry RD, Kerr NC, Haik BG, Wu S, Xiong X, Merchant TE. Visual Outcome After 54 Gy Conformal Radiation Therapy in Children with Optic Pathway Glioma. (*Poster*) Association for Research in Vision and Ophthalmology, May 2003.

Awdeh RM. Idiopathic Retinal Vasculitis, Aneurysms, and Neuro-retinitis (IRVAN). Doheny Eye Institute Grand Rounds, University of Southern California, June 27, 2003.

Awdeh RM. A Case of Flat Anterior Chamber: Aqueous Misdirection on Choroidal Detachment. (Discussant: Bruce Shields, MD) Connecticut State Glaucoma Society, May 14, 2003.

Awdeh RM. Pathogenesis of Aqueous Misdirection. Yale School of Medicine, Department of Ophthalmology, January 25, 2003.

Professional Licensures:

- Diplomate of the American Board of Ophthalmology
 - Board Certified by the ABO through 2020
- Florida Department of Health, Medical Board
 - License to practice medicine in the State of Florida
- Drug Enforcement Administration (DEA)
 - License to dispense prescription medication
- National Provider Identifier (NPI): 1215198239
- New York State, Medical Board
 - License to practice medicine in the State of New York

Editorial Board Memberships:

- Cataract and Refractive Surgery Today: Current Editorial Board Member
- Advanced Ocular Care: Current Editorial Board Member

Professional Awards:

- Best Doctors, 2011, 2012, 2013, 2014
- Premier Surgeon 250, listing of top 250 ophthalmic surgeons in the United States, 2010
- Ophthalmic Innovation Award, Duke University



Dr. Anthony J. Japour

THIS PAGE INTENTIONALLY LEFT BLANK



NAME: Japour Anthony J
 Last Name First Name Middle Initial

HOME ADDRESS: Miami Beach FL 33149
 Apt No. Home No./Street City State Zip Code

PHONE: --- ajjapour@me.com
 Home Work Fax Email Address

Business Name: Anthony Japour & Assoc. Medical Position: Director

Address: 200 Ocean Drive, 5A Miami Beach FL 33139
 Street City State Zip Code

Pursuant to City Code section 2-22(4) a and b: Members of agencies, boards, and committees shall be affiliated with the city; this requirement shall be fulfilled in the following ways: a) an individual shall have been a resident of the city for a minimum of six months; or b) an individual shall demonstrate ownership/interest for a minimum of six months in a business established in the city.

- Resident of Miami Beach for a minimum of six (6) months **Yes**
- Demonstrate an ownership/interest in a business in Miami Beach for a minimum of six (6) months: **Yes**
- Are you a registered voter in Miami Beach: **Yes**
- (Please circle one): I am now a resident of: **South Beach**
- I am applying for an appointment because I have special abilities, knowledge and experience. Please list below:
See full resume
- Are you presently a registered lobbyist with the City of Miami Beach? **No**

Please list your preferences in order of ranking [1] first choice [2] second choice, and [3] third choice. **Please note that only three (3) choices will be observed by the City Clerk's Office.** (Regular Boards of City)

- Choice 1:** Health Advisory Committee
- Choice 2:** Art in Public Places Committee
- Choice 3:** Ad Hoc Committee Centennial Celebration

Note: If applying for Youth Advisory Board, please indicate your affiliation with the Scott Rakow Youth Center: _____

1. Past service on the Youth Center Advisory Board: **No** Years of Service: _____
2. Present participation in Youth Center activities by your children **No** if yes, please list the names of your children, their ages, and which programs. List below:

- Have you ever been convicted of a felony: **No** If yes, please explain in detail: _____
- Do you currently have a violation(s) of City of Miami Beach codes: **No** If yes, please explain in detail: _____
- Do you currently owe the City of Miami Beach any money: **No** If yes, please explain in detail: _____
- Are you currently serving on any City Boards or Committees: **Yes** If yes, which board? _____

Health Advisory

- What organizations in the City of Miami Beach do you currently hold membership in?
- List all properties owned or have an interest in, which are located within the City of Miami Beach:

• I am now employed by the city of Miami Beach: **No** Which department?

being asked to comply with federal equal opportunity reporting requirements.

Gender: Male

Race/Ethnic Categories

What is your race? Mark one or more races to indicate what you consider yourself to be. **White**

Other Description:

Are you Spanish/Hispanic/ Latino? Mark the "No" box if not Spanish / Hispanic / Latino. **No**

Physically Challenged: **No**

NOTE: If appointed, you will be required to follow certain laws which apply to city board/committee members. These laws include, but are not limited to, the following:

- o Prohibition from directly or indirectly lobbying city personnel (Miami Beach City Code section 2-459).
- o Prohibition from contracting with the city (Miami-Dade County Code section 2-11.1).
- o Prohibition from lobbying before board/committee you have served on for period of one year after leaving office (Miami Beach Code section 2-26).
- o Requirement to disclose certain financial interests and gifts (Miami-Dade County Code section 2-11.1).
(re: CMB Community Development Advisory Committee): prohibition, during tenure and for one year after leaving office, from having any interest in or receiving any benefit from Community Development Block Grant funds for either yourself, or those with whom you have business or immediate family ties (CFR 570.611).

Upon request, copies of these laws may be obtained from the City Clerk.

"I hereby attest to the accuracy and truthfulness of the application and have received, read and will abide by Chapter 2, Article VII – of the City Code "Standards of Conduct for City Officers, Employees and Agency Members."

I Anthony Japour agreed to the following terms on 12/30/2014 9:29:30 AM

Received in the City Clerk's Office by:

Name of Deputy Clerk

Control No.

Date

Anthony J. Japour, M.D.

Curriculum Vitae



Anthony Japour & Associates, Medical and Scientific Consulting, Inc.
200 Ocean Drive, #5A
Miami Beach, FL 33139

Tel: 305.989.4500
Email: ajjapour@me.com

TABLE OF CONTENTS FOR CURRICULUM VITAE

No	Subject	Page No
1	EDUCATION	3
2	FULL-TIME ACADEMIC EXPERIENCE	3
3	PART-TIME ACADEMIC EXPERIENCE	3
4	NON-ACADEMIC EXPERIENCE	4
5	EMPLOYMENT RECORDS AT FIU	5
6	PUBLICATIONS IN DISCIPLINE	5
	Invited Papers in Professional Journals	5
	Peer Reviewed Research Articles	5
	Book Chapters	8
	Abstracts	8
	Other Publications/Books	16
7	PRESENTED LECTURES AND PAPERS	16
	Invited Lectures	16
	Oral Presentations at Conferences	18
	Poster Presentations at Conferences by Fellows	18
8	FUNDED RESEARCH	19
	External Funding as PI	19
	External Funding as Co-PI/Co-Investigator	19
	Students/Fellows Funding/Fellowships	19
9	PROFESSIONAL HONORS, PRIZES AND FELLOWSHIPS	20
	Local	20
	National	20
10	TEACHING	20
	List of courses taught at FIU	20
11	MENTORING (SCHOLARS & STUDENTS)	20
	Medical Residents	20
	Postdoctoral Fellows	20
12	OTHER PROFESSIONAL ACTIVITIES AND PUBLIC SERVICE	22
	Editorial Boards	22
	Journal Reviews	22
	Grant Reviews	22
	Conference Committees	22
	Conference Committees-AIDS Clinical Trials Group (ACTG)	23
	Others	23
	University Service	23

1. EDUCATION

Degree	Institution	Field	Dates
	University of Chicago Graduate School of Business, Chicago IL	Executive Training Program, Finance	2001
	Harvard Medical School Combined Infectious Diseases Program (Beth Israel Hospital, Brigham & Women's Hospital, Dana Farber Cancer Institute, Boston Children's Hospital), Boston, MA	Post-Doctoral Fellowship in Infectious Diseases	1989-1992
	Mount Auburn Hospital, Cambridge, MA	Residency in Internal Medicine	1987-1989
	Mount Auburn Hospital, Cambridge, MA	Internship in Internal Medicine	1986-1987
	Queen's Square London, England	4 th Year Elective Clerkship in Neurology	1986
MD	Northwestern University Medical School, Chicago, IL	Medicine	1983-1986
	Harvard School of Dental Medicine, Boston MA	Basic Sciences	1981-1982
BS	University of Michigan, Ann Arbor, MI	Liberal Arts	1977-1981

2. FULL-TIME ACADEMIC EXPERIENCE

Institution	Rank	Field	Dates
Harvard Medical School, Boston, MA	Assistant Professor	Internal Medicine/Infectious Diseases	1995-1996
Harvard Medical School, Boston, MA	Instructor	Internal Medicine/Infectious Diseases	1992-1995

3. PART-TIME ACADEMIC EXPERIENCE

Institution	Rank	Field	Dates
Jackson North Medical Center Jackson Health System, Miami FL Florida International University, Miami, FL	Consultant	Hepatitis, HIV, Infectious Diseases	2011-12
Molecular Microbiology & Infectious Diseases, Herbert Wertheim College of Medicine Florida International University, Miami, FL	Associate Professor	Infectious Diseases	2009-2013
Veteran's Administration Hospital, Miami, FL	Without Compensation Consultant	Infectious Disease	2006-2012
University of Miami, Miami, FL.	Voluntary Associate Professor	Internal Medicine	2004-2010

Center for Medical Ethics, University of Chicago Chicago, IL	Visiting Senior Fellow	Medical Ethics	2002- 2003
Medicine, Harvard Medical School, Boston, MA	Visiting Lecturer	Infectious Diseases	2002- 2003
Rush-Presbyterian St. Lukes' Medical School, Chicago, IL	Assistant Professor	Internal Medicine	2002- 2003
Harvard Medical School, Boston, MA	Assistant Clinical Professor	Internal Medicine	1996- 2001

4. NON-ACADEMIC EXPERIENCE

Place of Employment	Title	Dates
Elite Health Medical Group Miami Beach, FL	Health & Wellness Physician Director, Hepatitis C Program	2012-Present
Mount Sinai Medical Center Miami Beach, FL	Staff Physician	2012-Present
Anthony Japour & Associates, Medical and Scientific Consulting, Inc., Miami Beach, FL	Managing Director	2006-Present
Research Physicians Network Alliance Miami Beach, FL	Principal Investigator	2012-2013
Anthony Japour Medical and Scientific Consultant, Miami Beach, FL	Consultant	2002-2006
Abbott Laboratories, Global Medical Affairs, Abbott Park, IL	Global Director HIV & Immunology Franchises Marketed Product Development, Global Medical Affairs	2001-2002
Abbott Laboratories, Abbott Park, IL	Professional Development Director Physician Rotation Program/ CME Course Director, Global Medical Affairs	2001-2002
Abbott Laboratories, Abbott Park, IL	Medical Director HIV/Transplant Franchise, Medical Affairs	1999-2001
Abbott Laboratories, Abbott Park, IL	Associate Medical Director II Antiviral Venture, Pharmaceutical Products Division	1998-1999
Abbott Laboratories, Abbott Park, IL	Associate Medical Director I Antiviral Venture, Pharmaceutical Products Division	1996-1998
Beth Israel Deaconess Medical Center, Boston, MA	Senior Associate Physician	1995-1996

Beth Israel Deaconess Medical Center, Boston, Ma	Associate Physician	1992-1994
---	---------------------	-----------

5. EMPLOYMENT RECORD AT FIU

Rank	Dates
Associate Professor	2009-2013

6. PUBLICATIONS IN DISCIPLINE

No	Year	Authors, Title, Journal
Invited Papers in Professional Journals		
5	2003	J. Feinberg, A. Japour . Scientific and Ethical Considerations in Trial Design for Investigational Agents for the Treatment of Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> 36: 1-6.
4	1995	Japour, A.J. The Clinical Significance of HIV-1 Drug Resistance and the Impact on HIV Pathogenesis. <i>AIDS Clinical Care</i> 7(9).
3	1993	Collier, A., Henry, K., Japour, A.J. , van der Horst, C. Switching and Combining Antiretroviral Therapies - a Roundtable Discussion. <i>AIDS Clinical Care</i> 5:33-42.
2	1991	Japour, A.J. and Crumpacker, C.S. Zidovudine Resistance in HIV. <i>AIDS Clinical Care</i> 3:65-67.
1	1987	Japour, A.J. But First, A Little Chi Chi. <i>Massachusetts Medicine</i> .
Peer Reviewed Research Articles		
31	2002	S. Walmsley, B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, D. Johnson, R. LaLonde, A. Japour , S. Brun, E. Sun. Lopinavir-Ritonavir Versus Nelfinavir for Initial Treatment of HIV Infection. <i>New England Journal of Medicine</i> 346:2039-2046.
30	2002	Benson, C.A., Deeks, S.G., Brun, S.C., Gulick, R.M., Eron, J.J., Kessler, H.A., Murphy, R.L., Hicks, C., King, M., Wheeler, D., Feinberg, J., Stryker, R., Sax, P.E., Riddler, S., Thompson, M., Real, K., Hsu, A., Kempf, D., Japour, A.J. , Sun, E. Safety and Antiviral at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus 1-Infected Protease Inhibitor-Experienced. <i>The Journal of Infectious Diseases</i> 185:599-607.
29	2001	Kempf, D.J., Isaacson, J.D., King, M.S., Brun, S.C., Xu, Y., Real, K., Bernstein, B.M., Japour, A.J. , Sun, E., Rode, R.A. Identification of Genotypic Changes in Human Immunodeficiency Virus Protease that Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced Patients. <i>Journal of Virology</i> 75: 7462-7469.
28	2001	Murphy, R.L., Brun, S., Hicks, C., Eron, J. J., Gulick, R., King, M., White, A.C., Benson, C., Thompson, M., Kessler, H.A., Hammer, S., Bertz, R., Hsu, A., Japour, A. , Sun, E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naïve adults with HIV-1 infection: 48-week results. <i>AIDS</i> 15:1-9.
27	2000	Gisolf, E.H., Jurriaans, S., Pelgrom, J., van Wanseele, F., van der Ende, M.E., Brinkman, K., Borst, M.J, de Wolf, F., Japour, A.J. , Danner, S.A. The Effect of Treatment Intensification in HIV-Infection: A Study Comparing Treatment with

		Ritonavir/Saquinavir and Ritonavir/Saquinavir/Stavudine. <i>AIDS</i> 14:405-413.
26	2000	Welles, S.L., Pitt, J., Colgrove, R., McIntosh, K., Chung, P.H., Colson, A., Lockman, S., Fowler, M. G., Hanson, C., Landesman, S., Moye J., Rich, K.C., Zorrilla, C., Japour, A. J. HIV-1 Genotype Zidovudine Drug Resistance and the Risk of Maternal-Infant Transmission In the Women and Infant Transmission Study. <i>AIDS</i> 14:263-272.
25	1999	Colgrove, R., Japour, A. A Combinatorial Ledge: Reverse Transcriptase Fidelity, Total Body Viral Burden, and the Implications of Multiple-Drug HIV Therapy For the Evolution of Antiviral Resistance. <i>Antiviral Res</i> 41:45-56.
24	1999	Cameron, D.W., Japour, A.J. , XU, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C., Poretz, D., Markowitz, M., Follansbee, S., Angel, J.B., McMahan, D., Ho, D., Devanarayan, V., Rode, R., Salgo, M.P., Kempf, D.J., Granneman, R., Leonard, J.M., and Sun, E. Ritonavir and Saquinavir Combination Therapy for the Treatment of HIV Infection. <i>AIDS</i> 13:213-224.
23	1998	Demeter, L.M., D'Aquila, R., Weislow, O., Lorenzo, E., Erice, A., Fitzgibbon, J., Shafer, R., Richman, D., Howard, T.M., Zhao, Y., Fisher, E., Huang, D., Mayers, D., Sylvester, S., Arens, M., Sannerud, K., Rasheed, S., Johnson, V., Kuritzkes, D., Reichelderfer, P., Japour, A. Interlaboratory Concordance of DNA Sequence Analysis To Detect Reverse Transcriptase Mutations In HIV-1 Proviral DNA. <i>J. Virol. Methods</i> 75:93-104.
22	1998	Colgrove, R.C., Pitt, J., Chung, P.H., Welles, S.L., Japour, A.J. Selective Vertical Transmission of HIV-1 Antiretroviral Resistance Mutations. <i>AIDS</i> 12:2281-2288.
21	1998	Hsu, A., Granneman, G.R., Cao, G., Carothers, L., Japour, A.J. , El-Shourbagy, T., Dennis, S., Berg, J., Erdman, K., Leonard, J.M., Sun, E. Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers. <i>Antimicrob. Agents Chemo.</i> 42: 2784-2791.
20	1998	Sham, H., Kempf, D., Molla, A., Marsh, K., Kumar, G., Chen, C., Kati, W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Sudthida, V., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, nC., Jayanti, V., Grabowski, B., Granneman, R., Sun, E., Japour, A. , Leonard, J., Plattner, J., Norbeck, D. ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease. <i>Antimicrob. Agents Chemo.</i> 42:3218-3224.
19	1998	Fiscus, S.A., Hughes, M.D., Lathey, J.L., Pi, T., Jackson, B.J., Rasheed, S., Elbeik, T., Reichman, R., Japour, A.J. , Byington, R., Scott, W., Griffith, B.P., Katzenstein, D.A., Hammer, S.M. Changes in Virologic Markers as Predictors of CD4 Cell Decline and Progression of Disease in Human Immunodeficiency Virus Type 1-Infected Adults Treated with Nucleosides. <i>J. Infect. Dis.</i> 177:625-633.
18	1998	Kew, Y., Olsen, L.R., Japour, A.J. , Prasad, V.R. Insertions into the β 3- β 4 Hairpin Loop of HIV-1 Reverse Transcriptase Reveal a Role for Fingers Subdomain in Processive Polymerization. <i>J. Biol. Chem.</i> 273:7529-7537.
17	1998	Lathey, J.L., Hughes, M.D., Fiscus, S.A., Pi, T., Jackson, J.B., Rasheed, S., Elbeik, T., Reichman, R., Japour, A.J. , D'Aquila, R.T., Scott, W., Griffith, B.P., Hammer, S.M., Katzenstein, D.A. Variability and Prognostic Values of Virologic and CD4 Cell Measures in Human Immunodeficiency Virus Type 1-Infected Patients with 200-500 CD4 Cells/mm ³ (ACTG 175). <i>J. Infect. Dis.</i> 177:617-24.
16	1998	Kempf, D.J., Rode, R.A., Xu, Y., Sun, E., Heath-Chiozzi, M.E., Valdes, J., Japour, A.J. , Danner, S., Boucher, C., Molla, A., Leonard, J.M. The Duration of Viral Suppression During Protease Inhibitor Therapy for HIV-1 Infection is Predicted by Plasma HIV-1 RNA at the Nadir. <i>AIDS</i> 12:F9-F14.
15	1997	Race, E., Adelson-Mitty, J., Barlam, T., Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in

		Patients with Advanced HIV-1 Disease. <i>Lancet</i> 351:252-255.
14	1997	Marschner, I.C., Mayers, D.L., Erice, A., Smeaton, L., Johnson, V.A., Richman, D.D., Reichelderfer, P., Japour, A.J. Standardized Peripheral Blood Mononuclear Cell Culture Assay for Zidovudine Susceptibility Testing of Clinical Human Immunodeficiency Virus Type 1 Isolates: Effect of Reducing the Numbers of Replicates and Concentrations. <i>J. Clin. Microbiol.</i> 35:756-758.
13	1996	Katzenstein, D.A., Hammer, S.M., Hughes, M., Gundacker, H., Jackson, J.B., Fiscus, J., Rasheed, S., Elbeik, T., Reichman, R., Japour, A.J. , Merigan, T.C., Hirsch, M. The Relation of Virologic and Immunologic Markers to Clinical Outcomes After Nucleoside Therapy in HIV-Infected Adults With 200 to 500 CD4 Cells Per Cubic Millimeter. <i>New England J. Med.</i> 335:1091-1098.
12	1996	Shafer, R.W., Winters, M.A., Mayers, D., Japour, A.J. , Kuritzkes, D., Weislow, O., White, F., Erice, A., Sannerud, K., Iversen, A., Pena, F., Dimitrov, D., Frenkel, S., Reichelderfer, P.S. Inter-Laboratory Comparison of Sequence-Specific PCR and Ligase Detection Reaction to Detect an HIV-1 Drug Resistance Mutation. <i>J. Clin. Microbiol.</i> 34:1849-1853.
11	1996	Coombs, R.W., Welles, S.L., Hooper, C., Reichelderfer, P.S., D'Aquila, R.T., Japour, A.J. , Johnson, V.A., Kuritzkes, D.R., Richman, D.D., Kwok, S., Todd, J., Jackson, J.B., DeGruttola, V., Crumpacker, C.S., and Kahn, J. Association of Plasma Human Immunodeficiency Virus Type-1 RNA Level With Risk of Clinical Progression in Patients With Advanced Infection. <i>J. Infect. Dis.</i> 174:704-712.
10	1996	Japour, A.J. , Lertora, J.J., Meehan, P.M., Erice, A., Connor, J.D., Griffith, B.P., Clax, P.A., Holden-Wiltse, J., Hussey, S., Walesky, M., Cooney, E., Pollard, R., Timpone, J., McLaren, C., Johanneson, N., Wood, K., Booth, D.K., Bassiakos, Y., Crumpacker, C.S., for the AIDS Clinical Trials Group 231 Protocol Team. A Phase I Study of the Safety, Pharmacokinetics, and Antiviral Activity of Combination Didanosine and Ribavirin. <i>J. Acquired Immune Defic. Syndromes Hum. Retrovirol.</i> 13:235-246.
9	1995	Japour, A.J. , Welles, S., D'Aquila, R.T., Johnson, V.A., Richman, D.D., Coombs, R.W., Reichelderfer, P.S., Kahn, J., DeGruttola, V., Crumpacker, C.S., Kuritzkes, D.R. Prevalence and Clinical Significance of Zidovudine (ZDV) Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients Following Long-Term Zidovudine Treatment. <i>J. Infect. Dis.</i> 171:1172-1179.
8	1995	Welles, S., Jackson, J., Yen-Lieberman, B., Demeter, L., Japour, A.J. , Smeaton, L.M., Johnson, V., Kuritzkes, D., D'Aquila, R., Reichelderfer, P., Richman, D., Reichman, R., Fischl, M., Dolin, R., Coombs, R., Kahn, McLaren, C., Todd, J., Kwok, S., and Crumpacker, C. Prognostic Value of Plasma HIV-1 RNA Levels in Patients with Advanced HIV-1 Disease and With Little or No Zidovudine Therapy. <i>J. Infect. Dis.</i> 174:696-703.
7	1995	D'Aquila, R.T., Johnson, V.A., Welles, S.L., Japour, A.J. , Kuritzkes, D., DeGruttola, V., Reichelderfer, P.S., Coombs, R.W., Crumpacker, C., Kahn, J.O., Richman, D.D. Zidovudine Resistance and Human Immunodeficiency Virus Type 1 Disease Progression During Antiretroviral Therapy. <i>Annals Internal Med.</i> 122:401-408.
6	1995	Lan, Y., Japour, A.J. , Kim, S., Welles, S.L., Crumpacker, C.S., Cooper, E., Al-Attar, I., McIntosh, K. A Rapid, Direct Test for Zidovudine Susceptibility in Clinical Isolates of Human Immunodeficiency Virus Type 1 (HIV-1) From Infected Children. <i>Clinic. Diag. Virol.</i> 3:259-271.
5	1994	Mayers, D.L., Japour, A.J. , Arduino, J.M., Hammer, S.M., Reichman, R., Wagner, K.F., Chung, R., Lane, J., Crumpacker, C.S., McLeod, G.X., Beckett, L.A., Roberts, C.R., Winslow, D., Burke, D. and the RV43 Study Group. Dideoxynucleoside Resistance Emerges with Prolonged Zidovudine Monotherapy. <i>Antimicrob. Agents</i>

		<i>Chemo.</i> 38:307-314..
4	1994	Japour, A.J. , Fiscus, S.A., Arduino, J.M., Mayers, D.L., Reichelderfer, P.S., Kuritzkes, D.R. Standardized Microtiter Assay for Determination of Syncytium-Inducing Phenotypes of Clinical Human Immunodeficiency Virus Type 1 Isolates. <i>J. Clin. Microbiol.</i> 32:2291-2294.
3	1993	Japour, A.J. , Mayers, D.L., Johnson, V.A., Kuritzkes, D.R., Beckett, L.A., Arduino, J.M., Lane, J., Black, R.J., Reichelderfer, P.S., D'Aquila, R.T., Crumpacker, C.S. The RV-43 Study Group, The AIDS Clinical Trials Group Virology Committee Resistance Working Group. A Standardized Peripheral Blood Mononuclear Cell Culture Assay for the Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus-1 (HIV-1) Isolates. <i>Antimicrob. Agents Chemo.</i> 37:1095-1101.
2	1991	A.J. Japour , P.A. Chatis, H.A. Eigenrauch, C.S. Crumpacker. Detection of Human Immunodeficiency Virus Type 1 Clinical Isolates With Reduced Sensitivity to Zidovudine and Dideoxyinosine by RNA-RNA Hybridization. <i>PNAS</i> 88:3092-3096.
1	1983	Keith, D.A., Gundberg, C.M., Japour, A.J. , Arnoff, J., Alverez, N., Gallop, P.M. Vitamin K Dependent Proteins and Anticonvulsant Medications. <i>Clinic. Pharm. Therap.</i> 34:529-32.
Book Chapters		
4	2007	A.J. Japour . Informed Consent, Ethical Issues in Performing HIV Research. <i>Fundamentals of HIV Medicine</i> . American Association of HIV Medicine. Washington DC, 54.2:722-724.
3	2007	A.J. Japour . Ethical Conduct of Clinical Trials, IRBs, and Financial Conflicts of Interest, Ethical Issues in Performing HIV Research. <i>Fundamentals of HIV Medicine</i> . American Association of HIV Medicine, Washington DC 54.1:717-721.
2	1997	A.J. Japour . Management of CMV Disease. In Cotton DJ & Watts DH (eds): <i>Medical Management of AIDS in Women</i> , New York: John Wiley & Sons, Inc.
1	1997	A. Molla, A.J. Japour . HIV Protease Inhibitors. <i>Current Opinion in Infectious Diseases</i> 10:491-495.
Abstracts		
86	2009	Welles S., Lichtenberger P, Fertil J., Medina R., Cousino G., Romero J., Ullah E., Japour A. , Factors Associated with Antiretroviral Therapy Adherence (ART-AD) among HIV + Women in the Miami-Dade County Health Department AIDS Drug Assistance Program (MDC-ADAP). American Public Health Association 137 th Annual Meeting.
85	2007	Gagnon J., Welles S., Japour A. Factors affecting HIV therapy adherence amongst marginalized urban men who have sex with men (MSM). American Public Health Association 135 th Annual Meeting.
84	2006	Gulnik S., Afonina E., Eissenstat M., Parkin N., Japour A. , and Erickson J. SPI-256, a Highly Potent HIV Protease Inhibitor with Broad Activity against MDR Strains. 13 th Conference on Retroviruses and Opportunistic Infections, Denver, Colorado, February 5-8.
83	2002	Cameron, D., Angel, J., Ryan, J., Jiang, P., Rode, R., Farthing, C., Cohen, C., Mellors, J., Poretz, D., Markowitz, M., Ho, D., McMahon, D., Drennan, D., Seidler, T., Sun, E., Japour, A.J. Durability of Ritonavir (RTV) Saquinavir (SQV) Dual Protease Inhibitor Therapy in HIV infection: 5-Year Follow-up. 9 th CROI February 24-28, Seattle, WA.
82	2002	Cohen, C., Shen, Y., Rode, R., Cameron, D., Mellors, J., Farthing, C., Poretz, D., Markowitz, M., Ho, D., McMahon, D., Drennan, D., Selness, K., Sun, E., Kakuda, T., Japour, A.J. , Ryan, J. for the M96-462 Study Group Effect of Nucleoside (NRTI) Intensification on Prevalence of Morphologic Abnormalities (MoAs) at Year 5 of

		Ritonavir plus Saquinavir (SQV) Therapy in an HIV-Infected Cohort. 9 th CROI February 24-28, Seattle, WA.
81	2002	Steinberg, S., Venuto, R., Kuruvila, K., Taylor, D., Anil Kumar, M., First, M., Greco, R., Boodhoo, T., Singh, A., Ashraf, T., Japour, A. , Ryan, J. A Randomized, Open-label Preference Study of Gengraf [®] Compared to Neoral [®] in Stable Solid-organ Transplant Recipients., 7 th International Society of Pharmacoeconomics and Outcomes Research - ISPOR, Arlington, May 19-21. Published in <i>Value in Health</i> 6(3), 198-290.
80	2001	Harley, W., DeJesus, E., Pistole, M., Sension, M., Garrett, L., Nettler, S., Jiang, P., Rode, R., Ashraf, T., McMillan, F., Japour, A. A 24-Week Randomized, Controlled, Open-Label Evaluation of Adherence and Convenience of Continuing Indinavir Versus Switching to Ritonavir/Indinavir 400 mg/400 mg BID (The NICE Study). 8 th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 4-8.
79	2002	Hsu, A., Zolopa, A., Shulman, N., Havlir, D., Gallant, J., Race, E., Jiang, P., Boller, S., Swerdlow, J., Jasinsky, O., Renz, C., Japour, A. , Kempf, D., Sun, E. Final Analysis of Ritonavir (RTV) Intensification in Indinavir (IDV) Recipients with Detectable HIV RNA Levels. 8 th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February 4-8.
78	2001	Cohen, C., Ryan, J., Jiang, P., Cameron, D.W., Mellors, J., Kakuda, T., Japour, A.J. Effect of Nucleoside Intensification on Prevalence of Morphologic Abnormalities at Year 4 of Ritonavir + Saquinavir Therapy in an HIV-Infected Cohort. 1 st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7.
77	2001	Farthing, C., Ryan, J., Rode, R., Markowitz, M., Cameron, D.W., McMahon, D., Japour, A.J. Durability of Ritonavir + Saquinavir Dual Protease Inhibitor Therapy in HIV Infection: Four-Year Follow-Up. 1 st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7.
76	2001	King, M., Brun, S., Marsh, T., Real, K., Kempf, D., Japour, A. , Sun, E. Factors Affecting Long-Term Virologic Suppression in Phase II Studies of Lopinavir/ritonavir (LPV/r) in ARV-Naïve or PI-Experienced Patients. 1 st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7.
75	2001	Sension, M., Harley, W., DeJesus, E., Jiang, P., Garrett, L., McMillan, F., Clax, P., Japour, A. Final Analysis of a 24-Week Randomized, Controlled, Open-Label Evaluation of Adherence and Convenience of Continuing Indinavir vs. Switching to Ritonavir/Indinavir 400 mg/400 mg BID. 1 st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 7.
74	2001	Hicks, C., Brun, S., King, M., Marsh, T., Deeks, S., Benson, C., Gulick, R., Kessler, H., Murphy, R., Wheeler, D., Feinberg, J., Eron, J., Sax, P., Stryker, R., Riddler, S., Thompson, M., Richards, B., Kempf, D., Japour, A. , Sun, E. for the M97-765 Study. Kaletra (Lopinavir/Ritonavir) Therapy in Single Protease Inhibitor Experienced Patients: 144 Week Follow Up. 8 th European Conference on Clinical Aspects and Treatment of HIV-Infection, Athens, October 28-31.
73	2001	Perrin, L., King, M., Brun, S., Yerly, S., Marsh, T., Travers, N., Real, K., Japour, A. , Sun, E. Failure to Achieve HIV RNA \leq 3 Copies/mL Does Not Predict Loss of Virologic Response to Kaletra (Lopinavir/Ritonavir) Therapy through 3 Years. 41 st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19.
72	2001	Piliero, P.J., Preston, S.L., Japour, A.J. , Stevens, R.C., Morvillo, C., Drusano, G.L. Pharmacokinetics (Pk) of the Combination of Ritonavir (RTV) Plus Saquinavir (SQV), with and without Efavirenz (EFV), in Health Volunteers. 41 st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19.
71	2000	Coplan, P., Cormier, K., Japour, A. , Mardit-Kremers, H., Nikas, A., Lewis, R., Xu, Y.

		Myocardial Infarction Incidence in Clinical Trail of 4 Protease Inhibitors. 7 th Conference on Retroviruses and Opportunistic Infections, January 30-February 2.
70	2000	Gulick, R., King, M., Brun, S., Real, K., Murphy, R., Hick, C., Eron, J., Thommes, J., Thompson, M., White, C., Benson, C., Albrecht, M., Kessler, H., Hsu, A., Bertz, R., Kempf, D., Sun, E., Japour, A. ABT-378/Ritonavir (ABT-378/r) in Antiretroviral-Naïve HI+ Patients 72 Weeks. 7 th Conference on Retroviruses and Opportunistic Infections, January 30-February 2.
69	2000	Gisolf, E. H., Jurriaans, S., Pelgrom, J., Van Wanseele, F., Van Der Ende, M. E., Brinkman, K., Borst, M. J., De Wolf, F., Sun, E., Japour, A. , Danner, S. A. Ritonavir/Saquinavir Versus Ritonavir/Saquinavir/Stavudine in HIV-1-Infected Individuals During 48 Weeks: The Effect of treatment Intensifications. 7 th Conference on Retroviruses and Opportunistic Infections, January 30-February 2.
68	2000	Deeks, S., Brun, S., XU, Y., Real, K., Benson, C., Kessler, H., Murphy, R., Wheeler, D., Hicks, C., Eron, E., Feinberg, J., Gulick, R., Sax, P., Stryker, R., Riddler, S., Thompson, M., King, M., Potthoff, A., Hsu, A., Bertz, R., Molla, A., Mo, H., Kempf, D., Japour, A. , Sun, E. ABT-378/Ritonavir (ABT-378/r) Suppresses HIV RNA to <400 Copies/ml in 84% of PI-Experienced Patients at 48 Weeks. 7 th Conference on Retroviruses and Opportunistic Infections, January 30-February 2.
67	2000	Cameron, D.W., Xu, Y., Rode, R., Cohen, C., Mellors, J., Farthing, C., Poretz, D., Markowitz, M., Ho, D., McMahon, D., Drennan, D., Hill, L., Sun, E., Japour, A. Three-Year Follow-Up and Conditional Outcomes Survival Analysis of Ritonavir (RTV) plus Saquinavir (SQV) Therapy in HIV Infection. 7 th Conference on Retroviruses and Opportunistic Infections, January 30-February 2.
66	2000	Shulman, N., Zolopa, A., Havlir, D., Gallant, J., Race, E., Lam, W., Hill, L., Japour, A. , Kempf, D., Sun, E., Hsu, A. Ritonavir Intensification in Indinavir Recipients with Detectable HIV RNA Levels. 7 th Conference on Retroviruses and Opportunistic Infections, January 30-February 2.
65	2000	Pitt, J., Colgrove, R., Thompson, B., Japour, A. , Welles, S. Association of Maternal ZDV Use during Pregnancy and Infant ZDV Genotypic Resistance with Rapid Disease Progression among Infants in the WITS. 7 th Conference on Retroviruses and Opportunistic Infections, January 30-February 2.
64	2000	Kempf, D., Xu, Y., Brun, S., King, M., Mo, H., Real, K., Bernstein, B., Hertogs, K., Larder, B., Molla, A., Japour, A. , Sun, E. Baseline Genotype Phenotype Do Not Predict Response to ABT-378/Ritonavir in PI-Experienced Patients at 24 and 48 Weeks. 7 th Conference on Retroviruses and Opportunistic Infections, January 30-February 2.
63	2000	Molla, A., Brun, S., Mo, H., Real, K., Poddig, J., Bernstein, B., Hertogs, K., Larder, B., Lie, Y., Hellmann, N., Vasavanonda, S., Chernyavskiy, T., Freimuth, W., Japour, A. , Sun, E., Kempf, D. Genotypic and Phenotypic Analysis of Viral Isolates from Subjects with Detectable Viral Load on Therapy With ABT-378/Ritonavir (ABT-378/r). 4 th International Workshop on HIV Drug Resistance Focuses on New Anti-HIV Drugs Sitges, Portugal, June 12-16.
62	2000	Kempf, D., Isaacson, J., King, M., Brun, S., Xu, Y., Real, K., Lie, Y., Hellmann, N., Hertogs, K., Larder, B., Bernstein, B., Japour, A. , Sun, E., Rode, R. Genotypic Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV Isolates From Patients Failing Protease Inhibitor Therapy. 4 th International Workshop on HIV Drug Resistance Focuses on New Anti-HIV Drugs, Sitges, Portugal, June 12-16.
61	2000	Kessler, H., Brun, S., King, M., Marsh, T., Murphy, R., Eron, J., Gulick, R., Glesby, M., Hicks, C., Benson, C., Thompson, M., Thommes, J., Deeks, S., Wheeler, D., White, C., Stryker, R., Feinberg, J., Albrecht, A., Sax, P., Riddler, S., Real, K., Xu, Y., Japour, A. , Sun, E. Analysis of Safety Data from ABT-378/ritonavir (ABT-378/r) in Two Phase II

		Clinical Trials XIII International AIDS Conference, July 9-14.
60	2000	Thompson, M., Brun, S., Xu, X., Murphy, R., Eron, J., Gulick, R., Glesby, M., Hicks, C., Benson, C., Thommes, J., Kessler, H., Deeks, S., Wheeler, D., White, C., Stryker, R., Feinberg, J., Albrecht, M., Sax, P., Riddler, S., Real, K., King, M., Japour, A. , Sun, E., Analysis of Duration of Virologic Response in Two Phase II Studies of ABT-378/ritonavir (ABT-378/r) at 72 Weeks. XIII International AIDS Conference, July 9-14.
59	2000	Thompson, M., Murphy, R., Gulick, R., Hicks, C., Eron, J., Benson, C., Thommes, J., Kessler, H., Deeks, S., Wheeler, D., White, C., Stryker, R., Feinberg, J., Albrecht, M., Sax, P., Riddler, S., Real, K., King, M., Japour, A. , Sun, E., Analysis of Duration of Virologic Response in Two Phase II Studies of ABT-378/ritonavir (ABT-378/r) at 72 Weeks. XIII International AIDS Conference, July 9-14.
58	2000	DeJesus, E., Pistole, M., Fetchick, R., Lauermann, M., Roland, R., Garrett, L., Jiang, P., McMillan, F., Japour, A. A Randomized, Controlled, Open-Label Study Comparing the Adherence and Convenience of Continuing Indinavir Q8H vs. Switching to Norvir/Indinavir 400 mg/400 mg BID (The NICE Study). XIII International AIDS Conference, July 9-14.
57	2000	Hsu, A., Williams, L., Chiu, Y-L., Hill, L., McMillan, F., Lamm, J., Rynkiewicz, K., Foit, C., Ji, Q., Hutman, W., Ryan, J., Sun, E., Japour, A. Pharmacokinetic (PK) Interactions Between Ritonavir (RTV) and Amprenavir (APV) in Healthy Volunteers. XIII International AIDS Conference, July 9-14.
56	2000	Havli, D., Gallant, J., Race, E., Lam, W., Schulman, N., Zolopa, A., Ryan, J., Japour, A. , Kempf, D., Sun, E. Ritonavir Intensification in Indinavir Recipients: Tolerance, Antiviral Effect and Pharmacokinetics. XIII International AIDS Conference, July 9-14.
55	2000	Williams, L., O'Dea, R., Weinberg, M., Keene, M., Japour, A. , Centko, M., Bachand, J., Hsu, A., Hill, L., Lamm, J. High Incidence of Rash Associated with Amprenavir (APV) During a Pharmacokinetic (PK) Interaction Trial in HIV-Negative, Healthy Volunteer. XIII International AIDS Conference, July 9-14.
54	2000	Benson, C., King, M., Marsh, T., Murphy, R., Hicks, C., Thommes, J., Gulick, M., Thompson, M., White, C., Albrecht, M., Kessler, H., Hsu, A., Bertz, R., Kempf, D., Travers, N., Real, K., Japour, A. , Sun, E. ABT-378/ritonavir (ABT-378/r) in Antiretroviral-naïve HIV+ Patients: 96 Weeks. 40 th ICAAC Conference, Toronto, Canada, September 17-20.
53	2000	Brun, S., Kempf, D., Molla, A., Mo, H., Xu, Y., Real, K., Poddig, J., Hertogs, K.I., Larder, B., Freimuth, W., Japour, A. , Sun, E. Analysis of Viral Isolates Following Viral Load Rebound on Therapy with ABT-378/ritonavir (ABT-378/r). 40 th ICAAC Conference, Toronto, Canada, September 17-20.
52	2000	Feinberg, J., Brun, S., Marsh, T., Benson, C., Deeks, S., Kessler, H., Murphy, R., Gulick, R., Wheeler, D., Hicks, C., Eron, J., Sax, P., Stryker, R., Riddler, S., Thompson, M., Real, K., Hsu, A., Bertz, R., Kempf, D., Japour, A. , Sun, E. Durable Suppression of HIV+ RNA After Two Years of Kaletra (ABT-378/ritonavir) Therapy in Single Protease Inhibitor Experienced Patients. 40 th ICAAC Conference, Toronto, Canada, September 17-20.
51	2000	Stryker, R., Brun, S., King, M., Marsh, T., Murphy, R., Hicks, C., Eron, J., Thommes, J., Gulick, R., Glesby, M., Thompson, M., White, C., Benson, C., Albrecht, M., Kessler, H., Real, K., Japour, A. , Perrin, L., Sun, E. Kaletra (ABT-378/ritonavir) in Anti-retroviral-Naïve HIV+ Patients: Follow-up Beyond Two Years and Viral Load Suspension Below 3 Copies/mL. 40 th ICAAC Conference, Toronto, Canada, September 17-20.
50	2000	Benson, C., Brun, S., King, M., Real, K., Murphy, R., Hicks, C., Eron, J., Thommes, J., Gulick, R., Glesby, M., Thompson, M., White, C., Albrecht, M., Kessler, H., Poddig, J.,

		Sun, E., Japour, A. Two Year Follow-Up of ABT-378/Ritonavir (ABT-378 in Antiretroviral Naïve HIV + Patients. 40 th ICAAC Conference, Toronto, Canada, September 17-20.
49	2000	Bertz, R., Lam, W., Rynkiewicz, C., Foit, I., Benedek, W., Fiske, P., Bryan, P., Sylte, J., Brun, S., Japour, A. , Granneman, G.R., Sun, E. Assessment of the Pharmacokinetic Interaction Between ABT-378/ritonavir (ABT-378/r) and Efavirenz (EFV) in Healthy Volunteers and in HIV + Subjects. 40 th ICAAC Conference, Toronto, Canada, September 17-20.
48	2000	Feinberg, J., Brun, S. Marsh, T., King, M., Benson, C., Deeks, S., Kessler, H., Murphy, R., Gulick, R., Wheeler, D., Hicks, C., Eron, J., Sax, P., Stryker, R., Riddler, S., Thompson, M., Real, K., Hsu, A., Bertz, R., Kempf, D., Japour, A. , Sun, E. Durable suppression of HIV + RNA After Two Years of Kaletra (ABT-378/ritonavir) Therapy in Single Protease Inhibitor Experienced Patients. 5 th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, October 22-26.
47	2000	Stryker, R., Brun, S., King, M., Marsh, T., Murphy, R., Hicks, C., Eron, J., Thommes, J., Gulick, R., Glesby, M., Thompson, M., White, C., Benson, C., Albrecht, M., Kessler, H., Real, K., Japour, A. , Perrin, L., Sun, E. Kaletra (ABT-378/ritonavir) in Antiretroviral-Naïve HIV + Patients: Follow-up Beyond Two Years and Viral Load Suppression Below 3 Copies/mL. 5 th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, October 22-26.
46	2000	Cohen, C., Cameron, D., Xu, Y., Rode, R., Mellors, J., Farthing, C., Poretz, D., Markowitz, D., Ho, D., McMahon, D., Drennan, D., Selness, K., Ryan, J., Sun, E., Japour, A.J. Effect of NRTI Intensification on Prevalence of Body Composition Abnormalities at Week 144 of Ritonavir + Saquinavir Therapy in an HIV-Infected Cohort. 2 nd International Workshop on Adverse Drug Reactions and Lipdystrophy in HIV Toronto, CA, September 13-15.
45	1999	Murphy, R., King, M., Brun, S., Orth, K., Hicks, C., Eron, J., Thommes, J., Gulick, R., Thompson, M., White, C., Benson, C., Hammer, S., Kessler, H., Bertz, R., Hsu, A., Kempf, D., Sun, E., Japour, A. ABT-378/ritonavir Therapy in Antiretroviral-Naïve HIV-I Infected Patients for 24 weeks. 6 th Conference on Retroviruses and Opportunistic Infections, January 31 - February 4.
44	1999	Mo, H., Chernyavskiy, T., Lu, L., Staser, J., Cohen, C., Cameron, W., Markowitz, M., Xu, Y., Kohlbrenner, W., Sun, E., Kempf, D., Japour, A. , Molla, A. Characterization of HIV-1 in Patients Following Long Term RTV-SQV Therapy. 6 th Conference on Retroviruses and Opportunistic Infections, January 31 - February 4.
43	1999	Colgrove, R., Pitt, J., Japour, A. , Welles, S. Evolutionary Hotspot Around RT Codon 215 Evolves During Zidovudine Exposure. 6 th Conference on Retroviruses and Opportunistic Infections, January 31 - February 4.
42	1999	Hsu, A., Granneman, R., Xu, Y., Rode, R., Japour, A. , Leonard, J., Sun, E. Initial HIV Clearance Rates Do Not Predict Long-Term Antiviral Activity for Ritonavir-Saquinavir (R-S) Combination Therapy in HIV-Protease Inhibitor-Naïve Patient. 6 th Conference on Retroviruses and Opportunistic Infections, January 31 – February 4.
41	1999	Bertz, R., Lam, W., Brun, S., Kumar, G., Fields, C., Orth, K., Jennings, J., Hsu, A., Granneman, R., Japour, A. , Sun, E. Multiple-Dose Pharmacokinetics (PK) of ABT-378/Ritonavir (ABT-378/r) in HIV+ Subjects. 39 th ICAAC Conference on Antimicrobial Agents and Chemotherapy, September 26-29.
40	1999	Hsu, A., Lal, R., Bertz, R., Lam, W., Jennings, J., Brooks, R., Bryan, P., Granneman, R., Sun, E., Japour, A. ABT-378 and Ritonavir Exposures Are Not Predicted by Erythromycin Breath Test (ERMBT). 39 th ICAAC Conference on Antimicrobial Agents and Chemotherapy, September 26-29.

39	1999	Hicks, C., King, M., Brun, S., Real, K., Murphy, R., Eron, J., Thommes, J., Gulick, R., Glesby, M., Thompson, M., White, C., Benson, M., Albrecht, M., Kessler, H., Hsu, A., Bertz, R., Kempf, D., Japour, A. , & Sun, E. ABT-378/Ritonavir (ABT-378/R) in Antiretroviral Naïve HIV + Patients: 48 Weeks. 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, October 23-27.
38	1999	Lal, R., Bertz, R., Lam, W., Jennings, J., Brooks, R., Bryan, P., Sun, E., Granneman, G.R., & Japour, A. Evaluation of the Pharmacokinetics (PK) of the Concurrent Administration of ABT-378/Ritonavir (ABT-378/R) and Nevirapine (NVP). 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, October 23-27.
37	1998	Lal, R., Hsu, A., Granneman, G.R., El-Shourbagy, T., Johnson, M., Lam, W., Manning, L., Japour, A.J. , Sun, E. Abbott Laboratories, Illinois "Multiple Dose Safety, Tolerability and Pharmacokinetics of ABT-378 in Combination with Ritonavir." 5th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, February.
36	1998	Colgrove, R., Pitt, J., Chung, P., Welles, S., Japour, A.J. , Harvard Medical School, Boston, Massachusetts, Columbia University, and University of Minnesota, Minneapolis, Minnesota. Selective Vertical Transmission of HIV-1 Zidovudine Resistance Mutations. 5 th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.
35	1998	Mellors, J., Japour, A.J. , Cameron, W., Cohen, C., Farthing, C., Follansbee, S., Markowitz, M., Poretz, D., Ho, D., McMahon, D., Xu, Y., Rode, R., Hsu, A., Velo, C., Berg, J., Salgo, M., Leonard, J., Sun, E. Sustained Activity of Ritonavir (RTV) Saquinavir (SQV) in Protease Inhibitor-Naïve Patients After 72 Weeks. 5 th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois.
34	1998	Cameron, D.W., Japour, A.J. , Mellors, C., Farthing, C., Cohen, C., Markowitz, M., Poretz, D., Follansbee, D., Ho, D., McMahon, D., Berg, J., Nieves, J., Xu, Y., Rode, R., Salgo, M., Leonard, J., Sun, E. Antiretroviral Safety & Durability of Ritonavir (RTV)-Saquinavir (SQV) in Protease Inhibitor-Naïve Patients in Year Two of Follow-up. 5 th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, February.
33	1998	Japour, A.J. , Kempf, D., Mo, H., Chernyavskiy, T., Kohlbrenner, W., Sun, E., Molla, A. HIV Protease Mutations Following Ritonavir-Saquinavir Therapy and Long-Term Outcome on Plasma Viral Load Following an Intensification Strategy. 2 nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, June 24-27.
32	1998	Hsu, A., Granneman, R., Molla, A., Vasavanonda, S., Japour, A. , Kempf, D., Sun, E. Ritonavir-Containing Dual Protease Inhibitor Regimens May Have Synergistic Antiviral Effects in Patients - Base on In Vitro Model. 12 th World AIDS Conference, Geneva, Switzerland, June 28 - July 3.
31	1998	Mellors, J., Japour, A. , Leonard, J., Sun, E., Xu, Y., Salgo, M., M97-462 Study Groups. Ritonavir (RTV)-Saquinavir (SQV) in Protease Inhibitor-Naïve Patients after 72 Weeks. 12 th World AIDS Conference, Geneva, Switzerland, June 28 - July 3.
30	1998	Gisolf, E.H., De Wolf, F., Pelgrom, J., Van Wanseele, F., Popescu, M., Japour, A. , Danner, S.A., Van Leeuwen, R. Treatment of Ritonavir (RTV)/Saquinavir (SQV) Versus RTV/SQV/Stavudine (d4T) (The Prometheus Study): Preliminary Results. 12 th World AIDS Conference, Geneva, Switzerland, June 28 - July 3.
29	1997	Race, E., Adelson-Mitty, J., Barlam, T., and Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1 Disease. 4 th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 352.
28	1997	Colgrove, R., Japour, A.J. Mathematical Modeling of Within-Patient Evolution of

		HIV-1 Antiretroviral Resistance as a Function of HIV Reverse Transcriptase Fidelity and Total-Body HIV Virion Burden Predicts Sharp Non-linear Superiority of Three-drug Over Two-drug Therapeutic Regimens. 4 th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 406.
27	1997	Race, E., Reimann, K., Letvin, N. and Japour, A.J. Recurrence of Trimethoprim-Sulfamethoxazole TMP-SMX Hypersensitivity Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1. 4 th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 535.
26	1997	Sun, E., Xu, Y., Hsu, A., Japour, A.J. , Korneyeva, M., Molla, A., Kempf, D., Leonard, J., and The Ritonavir-Saquinavir Study Group. Predictability of Response to Ritonavir-Saquinavir (RTV-SQV) Combination Therapy. Keystone, April.
25	1997	Molla, A., Korneyeva, M., Chernyavskiy, T., Colgrove, R., Chung, P., Japour, A.J. , Mellors, J., Xu, Y., Rode, R., Hsu, A., Granneman, G., Kempf, D., Leonard, J., Sun, E. and M96-462 Study Team. Characterization of HIV-1 Protease (PR) Mutations, Compliance, and Drug Concentrations in Patients Who Have an HIV RNA Rebound on Ritonavir-Saquinavir (RTV-SQV). International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida, 83, June 25-28.
24	1997	Welles, S., Pitt, J., Colgrove, R., McIntosh, K., Chung, P., Colson, A., Lockman, S., Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J., Rich, K., Zorilla, C., Japour, A.J. Molecular ZDV-Resistance and the Risk of Perinatal HIV-1 Transmission in the Women & Infants Transmission Study (WITS). Infectious Disease Society of America, San Francisco, California, September.
23	1997	Lal, R., Hsu, A., Chen, P., Dennis, S., El Shourbagy, T., Locke, C., Lam, W., Japour, A.J. , Leonard, J., Granneman, G.R., Sun, E. Single Dose Pharmacokinetics of ABT-378 in Combination with Ritonavir. 37 th ICAAC. September 28-October 1.
22	1997	Gisolf, E., Colebunders, R., Van Wanseele, F., Van Der Ende, M., Koopmans, P., Portegies, P., Hoetelmans, R., Japour, A.J. , Ward, P., De Wolf, F., Danner, S., on behalf of the Prometheus Study Group. Treatment with Ritonavir/Saquinavir Versus Ritonavir/Saquinavir/Stavudine. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, Germany, 354, October.
21	1995	Japour, A.J. , Lertora, J., Meehan, P., Clax, P., Connor, J., Pollard, R., McLaren, C., Johannesson, N., Erice, A., Cooney, E., Holden-Wiltse, J., Hussey, S., Walesky, M., Wood, K., Booth, D., Purdue, L., Greenspan, D., Kasdan, P., Basiakos, Y., Timpone, J., Pettinelli, C. and Crumpacker, C. A Phase I Study of the Safety, Tolerance and Pharmacokinetics of Combination Didanosine/Ribavirin for HIV Disease (ACTG 231). 2nd National Conference on Human Retroviruses, Washington, D.C.102.
20	1995	Welles, S., Jackson, J., Yen-Lieberman, B., Demeter, L., Japour, A. , Johnson, V., Kuritzkes, D., D'Aquila, R., Reichelderfer, P., Richman, D., Reichman, R., McLaren, C., Todd, J., Kwok, S., Fischl, M., Dolin, R. and Crumpacker, C. Prognostic Capacity of Plasma HIV-1 RNA Copy Number in ACTG 116A. 2nd National Conference on Human Retroviruses, Washington, D.C. 96.
19	1995	Japour, A.J. , Drosopoulos, W., Katapodis, N., Chung, P.H., Kew, Y., Prasad, V. Saturation Mutagenesis of the HIV-1 RT b3- b4 Hairpin Reveals Novel Mutations Conferring Dideoxynucleoside Triphosphate Resistance. Fourth Workshop on Viral Resistance, Annapolis, Maryland.
18	1995	Japour, A.J. & Pitt, J. Maternal-Infant Transmission of Zidovudine-Resistant (ZDV ^R) HIV-1. Infectious Diseases Society of America Meetings, San Francisco, California.
17	1995	Japour, A.J. , Kim, S., Greene, R., Joseph, R., Chatis, P. Clinical HIV-1 Isolates Displaying ddI-Resistance in Culture May be Unstable With Serial Passage. 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco,

		California, I280.
16	1995	Chatis, P.A., Brewster, F., Joseph, R.A., Greene, R.A., Japour, A.J. A Direct Method for Detection of Nevirapine Resistance in HIV-1 Clinical Isolates. 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California, I281.
15	1995	Demeter, L., Sannerud, K., Mayers, D., Fitzgibbon, J., Sylvester, S., Arens, M., Fisher, E., Shafer, R., Zhao, Y., Huang, D., Reichelderfer, P., Johnson, V.A., Richman, D., Rasheed, D., Kuritzkes, D., and Japour, A.J. , for the ACTG Genotypic Resistance Working Group. Interlaboratory Concordance of DNA Sequence Analysis of the HIV-1 Reverse Transcriptase. 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, I284.
14	1995	Erice, A., Brambilla, D., Demeter, L., Penas, J., Brewster, F., Stellrecht, K., Reichelderfer, P., Mayers, D., and Japour, A.J. , for the ACTG Virology Committee. Zidovudine (ZDV) Susceptibility Screening Assay for Clinical HIV Isolates. 35 th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, I285.
13	1994	Greene, R.A., Japour, A. , Joseph, R., Kasila, P., Litt, G., Chatis, P. A Direct Method for Detection of ddi Resistance in HIV-1 Clinical Isolates. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October, I214.
12	1993	Japour, A.J. , Chatis, P., Kim, S., Crumpacker, C.S. HIV-1 DDI-Resistance Overcome With Combination DDI/Ribavirin. IX International Conference on AIDS, Berlin, Germany, Abstract #PoA26-0640, June.
11	1993	Japour, A.J. , Fiscus, S., Mayers, D., Reichelderfer, P., Kuritzkes, D. Microtiter Modification of the MT-2 Syncytia Assay. IX International Conference on AIDS, Berlin, Germany, PoB41-2484, June.
10	1993	D'Aquila, R., Johnson, V., Kuritzkes, D., Japour, A.J. , Crumpacker, C., Richman, D. HIV-1 Drug Resistance and Syncytium-Inducing Phenotype: Associations With Disease Progression Among ACTG 116B/117 Subjects. IX International Conference on AIDS, Berlin, Germany, PoB26-2046, June.
9	1993	Lan, Y., Japour, A.J. , Kim, S., Crumpacker, C.S., Welles, S.L., McIntosh, K. A Rapid, Direct Test for Zidovudine Susceptibility in Clinical Isolates of Human Immunodeficiency Virus Type 1 (HIV-1) From Infected Children. IX International Conference on AIDS, Berlin, Germany, PoB262048, June.
8	1993	Kuritzkes, D.R., Welles, S., Johnson, V.A., Crumpacker, C.S., DeGruttola, V., Japour, A.J. The ACTG 116B/117 Virology Resistance Team. "Baseline Prevalence and Clinical Significance of Zidovudine (ZDV) Resistance Mutations in HIV-1 Isolates From Patients in ACTG Protocol 116B/117. Third Workshop on Viral Resistance, Washington, D.C., September.
7	1992	Japour, A.J. , Kuritzkes, D., Johnson, V., Mayers, D., Beckett, L., Arduino, J.M., D'Aquila, R., Crumpacker, C.S. Consensus Protocol to Measure Antiviral Resistance in Clinical HIV-1 Isolates. VIII International Conference on AIDS, Amsterdam, The Netherlands, Abstract #PoA 2484, July.
6	1992	Johnson, V., Balfour, H., Beckett, L., Cheseboro, B., Crumpacker, C., Haberzetti, C., Japour, A.J. , Katzenstein, D., Kuritzkes, D., Mayers, D., McIntosh, K., Rangan, S., Reichman, R., Richman, D., Scott, W., D'Aquila, R., AIDS Clinical Trials Group Virology Committee Virus Resistance Working Group. Inter-Laboratory Variability of Anti-HIV-1 Susceptibility Testing. VIII International Conference on AIDS, Amsterdam, The Netherlands, Abstract #PoA2310, July.
5	1992	Japour, A.J. , Kim, L., Chatis, P.A., Beckett, L., Arduino, J.M., Ecto, L., Chapman, B., Crumpacker, C.S. Serial HIV-1 ZDV and DDI Susceptibility in a Cohort of Subjects

		Enrolled in Three Antiviral Trials. VIII International Conference on AIDS, Amsterdam, The Netherlands, Abstract #PoB3572, July.
4	1992	Japour, A.J. , Mayers, D., Arduino, J.M., Beckett, L., Crumpacker, C.S. ZDV & ddI Susceptibility Correlates in Clinical HIV-1 Isolates. Infectious Diseases Society of America Annual Meeting, Anaheim, California.
3	1991	Japour, A.J. , Chatis, P.A., Kim, L., Crumpacker, C.S. HIV Susceptibility Testing in AIDS Clinical Trials. Seventh International Conference on AIDS, Florence, Italy, June.
2	1991	Japour, A.J. , Chatis, P.A., Eigenrauch, H., Kim, L., Crumpacker, C.S. ddI Potentiation by Ribavirin. Seventh International Conference on AIDS, Florence, Italy, June.
1	1990	Japour, A.J. , Eigenrauch, H.A., Chatis, P.A., Crumpacker, C.S. AZT-Resistant HIV Detection by RNA-RNA Hybridization. Sixth International Conference on AIDS, San Francisco, California, USA. Abstract #F.A.336, June.
Other Publications/Books		
1	2006	Japour A. , Massaro, M., Nordstrom D., Silberman C., Provost D., <i>Phase IV trial, observational study or patient registry: Which? When? Why?</i> at: http://www.ppd.com

7. PRESENTED LECTURES AND PAPERS

Invited Lectures		
No	Date	Venue, Date, Title
62	7/2014	<i>SOVALDI® (sofosbuvir) Roundtable Discussion: Clinical Considerations in Patient Management</i> , Coral Gables, FL
61	4/2014	<i>Transforming the Treatment Paradigm, Review of SOVALDI®(sofosbuvir)</i> , Miami Beach, FL
60	3/2014	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Palm Harbor, FL
59	3/2014	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Florida Center for Gastroenterology, Largo, FL
58	3/2014	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , St. Petersburg, FL
57	3/2014	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , GastroHealth, Miami, FL
56	2/2014	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Tampa, FL
55	1/2014	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Palm Beach, FL
54	1/2014	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Punta Gorda, FL
53	1/2014	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Savannah, GA
52	12/2013	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Orlando, FL
51	12/2013	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Miami Beach, FL
50	12/2013	<i>Once Daily Olysio (simeprevir) 150 mg- Clinical Overview</i> , Bonita Springs, FL
49	11/2013	<i>Hepatitis C: Past, Present, Future</i> , Borinquen Medical Centers of Miami Dade, Miami, FL
48	9/2013	<i>Hepatitis C Medications & Side Effects</i> , Hepatitis C Support Group, Miami Beach, FL
47	8/2013	<i>Hepatitis C: Past, Present, Future</i> , Mount Sinai Medical Center Medical Grand Rounds CME Program, Miami Beach, FL

46	7/2013	<i>Treatment-Naïve Adult Patient with Chronic HCV G1 Infection who has Compensated Liver Disease, Miami, FL</i>
45	6/2013	<i>Addressing Chronic Hepatitis C in Primary Care: Integrating Recent Medical Recommendations, Borinquen Medical Center, Miami, FL</i>
44	5/2013	<i>Addressing Chronic Hepatitis C in Primary Care: Integrating Recent Medical Recommendations, Family Care at Bardmoor, Largo, FL</i>
43	5/2013	<i>Addressing Chronic Hepatitis C in Primary Care: Integrating Recent Medical Recommendations, Indian Shores, FL</i>
42	4/2013	<i>Treatment-Naïve Adult Patient with Chronic HCV G1 Infection who has Compensated Liver Disease, Fort Myers, FL</i>
41	4/2013	<i>Today's Chronic Hepatitis C Patient: Viral/Patient Factors and Predicting Disease Progression, Digestive Care Center, North Miami, FL</i>
40	3/2013	<i>Treatment-Naïve Adult Patient with Chronic HCV G1 Infection who has Compensated Liver Disease, Macon, GA</i>
39	3/2013	<i>Addressing Chronic Hepatitis C in Primary Care: Integrating Recent Medical Recommendations, Athens, GA</i>
38	3/2013	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Absolute Care, Atlanta, GA</i>
37	2/2013	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Tampa General Medical Group, Tampa, FL</i>
36	2/2013	<i>Treatment-Naïve Adult Patient with Chronic HCV G1 Infection who has Compensated Liver Disease, Miami Beach, FL</i>
35	1/2013	<i>Treatment-Naïve Adult Patient with Chronic HCV G1 Infection who has Compensated Liver Disease, Melbourne, FL</i>
34	1/2013	<i>Today's Chronic Hepatitis C Patient: Viral/Patient Factors and Predicting Disease Progression, Daytona, FL</i>
33	12/2012	<i>Advanced Liver Disease in Chronic HCV: Strategies to Help and Monitor Patients, Liver Transplant Unit at Broward General Medical Center, Fort Lauderdale, FL</i>
32	11/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Triple O Medical, Palm Beach, FL</i>
31	11/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Central Indiana Gastroenterology Group, Indianapolis, IN</i>
30	11/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Private Practice, Palm Beach, FL</i>
29	11/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Gastroenterology Care Center, Miami, FL</i>
28	10/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Digestie Medicine Associates, Miami, FL</i>
27	10/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, University of Maryland Medical Center, Baltimore, MD</i>
26	9/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, St. Petersburg, FL</i>
25	8/2012	<i>Management of Chronic Hepatitis C Infection, One Patient at a Time, West Palm Beach, FL</i>
24	7/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Long Beach, CA</i>
23	7/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice, Los Angeles, CA</i>

22	5/2012	<i>Management of Chronic Hepatitis C Infection, One Patient at a Time</i> , Miami Beach, FL
21	5/2012	<i>Current Treatments for Chronic HCV: Translating Clinical Studies into Clinical Practice</i> , Augusta, GA
20	9/2011	Jackson North Medical Center Obstetrics & Gynecology, September 2011, <i>Hepatitis C Diagnosis and Treatment in Pregnant Women-New Directions in Hepatitis C treatment</i>
19	8/2011	Jackson North Medical Center Radio Show, August 2011, <i>Hepatitis C in the Community-Epidemiology, Diagnosis a& New Treatment Directions in Hepatitis C</i>
18	1/2011	Florida International University College of Medicine, <i>Syphilis</i>
17	10/2010	BioFlorida Annual Conference, Ft. Lauderdale, FL, Keynote Address, <i>Policy Implications for An Evolving Biosciences and Health Care Industry.</i>
16	01/2010	Florida International University College of Medicine, <i>Syphilis</i>
15	11/2009	American Bar Association, AIDS Coordinating Committee, <i>New HIV Infections in the United States.</i>
14	12/2009	Florida International University College of Medicine, <i>Infectious Diseases as Agents of Bioterrorism</i>
13	02/2009	Northwestern University, Keynote Address, Alumni Dance Marathon Dinner, <i>The HIV/AIDS Battle in the 21st Century.</i>
12	11/2008	Cruise Line International Association, Miami, FL, <i>Avian Influenza</i>
11	11/2007	Cruise Line International Association, Miami, FL, <i>Avian Influenza</i>
10	2007	Seatrade, Miami Beach, FL, <i>Avian Influenza</i>
9	2007	Miami Beach City Hall, Miami Beach, FL, <i>Avian Influenza- History and Present Threat</i>
8	08/2006	Centers for Disease Control, Florida department of health, Miami-Dade County Health Department, International Conference of Cruise Lines, <i>Royal Caribbean Cruises Avian Influenza (H5N1 Business Continuity and Shipboard Preparedness Planning)</i>
7	2006	International Conference of Cruise Lines, <i>Avian Influenza- History and Present Threat</i>
6	2000-2003	Academic Medical Centers in the US, <i>Where Science Meets Ethics in Clinical Trials: The HIV/AIDS Paradigm</i>
5	1996-2002	Harvard HIV CME Course, <i>Antiviral Drug Resistance or Where Science Meets Ethics in Clinical Trials: The HIV/AIDS Paradigm</i>
4	1995-2002	Infectious Diseases Training Program, Beth Israel-Deaconess Medical Center, <i>Antiretroviral Therapy for HIV Disease</i>
3	1992-1995	Harvard Medical School, Clinical Pharmacology & Therapeutics course HST 350, <i>Molecular Structure of Drug-Resistant HIV-1</i>
2	1990-1995	Beth Israel Hospital Medical Housestaff Lecture Series, <i>Syphilis in the AIDS Era</i>
1	1989-1995	Harvard Medical School, Infectious Diseases course 513MJ, <i>Syphilis in the AIDS Era</i>
Oral Presentations at Conferences		
No	Date	Authors, Title, Venue

1	1998	Japour, A., Murphy, R., Hicks, C., Eron, J., Yetzer, E., Hammer, S., Orth, K. Safety & Efficacy of ABT-378/Ritonavir in Antiretroviral-Naïve HIV Patients: Preliminary Phase II Results. 12 th World AIDS Conference, Geneva, Switzerland, June 28
Poster Presentations at Conferences by Fellows		
No	Date	Authors, Title, Venue
4	1997	Welles, S., Pitt, J., Colgrove, R. , McIntosh, K., Chung, P., Colson, A., Lockman, S. , Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J., Rich, K., Zorilla, C., Japour, A.J. Molecular ZDV-Resistance and the Risk of Perinatal HIV-1 Transmission in the Women & Infants Transmission Study (WITS). Infectious Disease Society of America, San Francisco, California, September
3	1997	Race, E., Adelson-Mitty, J. , Barlam, T., and Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1 Disease. 4 th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 352
2	1997	Colgrove, R. , Japour, A.J. Mathematical Modeling of Within-Patient Evolution of HIV-1 Antiretroviral Resistance as a Function of HIV Reverse Transcriptase Fidelity and Total-Body HIV Virion Burden Predicts Sharp Non-linear Superiority of Three-drug Over Two-drug Therapeutic Regimens. 4 th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 406
1	1997	Race, E. , Reimann, K., Letvin, N. and Japour, A.J. Recurrence of Trimethoprim-Sulfamethoxazole TMP-SMX Hypersensitivity Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1. 4 th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 535

8. FUNDED RESEARCH

No	Project Title	Agency	Project Dates
External Funding as PI			
10	A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination with Statin Therapy in Patients with Clinically Evident Cardiovascular Disease	Amgen	2013
9	A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Disease and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial) Amarin Pharma, Inc	Amarin Pharma, Inc.	2012-2013
8	SABA: A study of factors that affect adherence to HIV therapy and safer sex behaviors among women in the Miami-Dade County's AIDS Drug Assistance Program	Miami-Dade County Health Department AIDS Program	2007-2009
7	FOCUS: A study of factors that affect adherence to HIV	Miami-Dade	2004-2007

	therapy and safer sex behaviors among men who have sex with men in the Miami-Dade County's AIDS Drug Assistance Program.	County Health Department AIDS Program	
6	Intravenous Infusion in HIV-Positive Patients	Hybridon	1996
5	Maternal-Infant Transmission of ZDV-Resistant HIV-1 in the Women and Infants Transmission Study	NIH-NIAID	1995-1999
4	Maternal-Infant Transmission of ZDV-Resistant HIV-1	Pediatric AIDS Foundation	1994-1996
3	HIV-1 Zidovudine and Didanosine Resistance Detection	DuPont-NEN Life Sciences	1994-1996
2	Drug Resistant HIV-1 RT-Molecular Structure and Function	NIH-NIAID	1992-1996
1	Detection of HIV RNA in Patients Blood	American Foundation for AIDS Research	1989-1992
External Funding as Co-PI/Co-Investigator			
3	Biological Response Toolkit for Florida Hospitals. Development, production and training kit.	Florida Department of Health (subcontract to Jackson Health System)	2006-2007
2	Harvard Advanced Technical Laboratory Adult AIDS Clinical Trial Group	NIH-NIAID	1995-1996
1	Harvard/Boston City Hospital AIDS Clinical Trial Group	NIH-NIAID	1992-1996
Students/Fellows Funding/Fellowships			
No	Project Title	Agency	Project Dates
1	Elizabeth Race, M.D. (Fellowship) Clinical Investigator Training Program	Harvard/MIT Health Sciences Technology Program	1996-1998

9. PROFESSIONAL HONORS, PRIZES AND FELLOWSHIPS

Local		
No	Date	Honor
2	2013	<i>Best of 2013- Best MD, Miami Sun Post, Miami, FL</i>
1	2003	Key to the City of Miami Beach, City of Miami Beach, FL
National		
No	Date	Honor
3	2000	President's Award, Abbott Laboratories
2	1992-1996	Physician-Scientist Award, National Institute of Allergy and Infectious Diseases

1	1989-1992	Scholar for the American Foundation for AIDS Research
---	-----------	---

10. TEACHING

List of courses taught at FIU			
Courses other than Student Research Labs			
Course Name	Course Number	Fall	Spring
Medical Students			
Microbes, Infection and Immunology	BMS6300	2009-2013	

11. MENTORING (SCHOLARS AND STUDENTS)

Medical Residents		
No	Date	Name, Affiliation, Project Title, Papers
2	1995	<p>Amy Colson, Beth Israel Hospital, Medical Resident, Boston, MA Title: Maternal-Infant HIV Drug Resistance Transmission Publications:</p> <ul style="list-style-type: none"> • Welles, S.L., Pitt, J., Colgrove, R., McIntosh, K., Chung, P.H., Colson, A., Lockman, S., Fowler, M. G., Hanson, C., Landesman, S., Moye J., Rich, K.C., Zorrilla, C., Japour, A. J. HIV-1 Genotype Zidovudine Drug Resistance and the Risk of Maternal-Infant Transmission In the Women and Infant Transmission Study. <i>AIDS</i> 14:263-272 • Welles, S., Pitt, J., Colgrove, R., McIntosh, K., Chung, P., Colson, A., Lockman, S., Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J., Rich, K., Zorrilla, C., Japour, A.J. Molecular ZDV-Resistance and the Risk of Perinatal HIV-1 Transmission in the Women & Infants Transmission Study (WITS). Infectious Disease Society of America, San Francisco, California, September
1	1995	<p>Shahin Lockman, Beth Israel Hospital, Medical Resident, Boston, MA Title: Maternal-Infant HIV Drug Resistance Transmission Publication:</p> <ul style="list-style-type: none"> • Welles, S.L., Pitt, J., Colgrove, R., McIntosh, K., Chung, P.H., Colson, A., Lockman, S., Fowler, M. G., Hanson, C., Landesman, S., Moye J., Rich, K.C., Zorrilla, C., Japour, A. J. HIV-1 Genotype Zidovudine Drug Resistance and the Risk of Maternal-Infant Transmission In the Women and Infant Transmission Study. <i>AIDS</i> 14:263-272 • Welles, S., Pitt, J., Colgrove, R., McIntosh, K., Chung, P., Colson, A., Lockman, S., Davenny, K., Fowler, M., Hansen, I., Landesman, S., Moye, J., Rich, K., Zorrilla, C., Japour, A.J. Molecular ZDV-Resistance and the Risk of Perinatal HIV-1 Transmission in the Women & Infants Transmission Study (WITS). Infectious Disease Society of America, San Francisco, California, September

Postdoctoral Fellows		
No	Date	Name, Affiliation, Project Title, Papers
4	1998	<p>Scott Brun, Physician Rotation Program, Abbott Laboratories Professional Development Program</p> <p>Title: Phase I/II Clinical Research Studies in HIV</p> <p>Publications:</p> <ul style="list-style-type: none"> Hicks, C., King, M., Brun, S., Real, K., Murphy, R., Eron, J., Thommes, J., Gulick, R., Glesby, M., Thompson, M., White, C., Benson, M., Albrecht, M., Kessler, H., Hsu, A. Bertz, R., Kempf, D., Japour, A., & Sun, E. ABT-378/Ritonavir (ABT-378/R) in Antiretroviral Naïve HIV + Patients: 48 Weeks. 7th European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, October 23-27 Bertz, R., Lam, W., Brun, S., Kumar, G., Fields, C., Orth, K., Jennings, J., Hsu, A., Granneman, R., Japour, A., Sun, E. Multiple-Dose Pharmacokinetics (PK) of ABT-378/Ritonavir (ABT-378/r) in HIV+ Subjects. 39th ICAAC Conference on Antimicrobial Agents and Chemotherapy, September 26-29 Murphy, R., King, M., Brun, S., Orth, K., Hicks, C., Eron, J., Thommes, J., Gulick, R., Thompson, M., White, C., Benson, C., Hammer, S., Kessler, H., Bertz, R., Hsu, A., Kempf, D., Sun, E., Japour, A. ABT-378/ritonavir Therapy in Antiretroviral-Naïve HIV-I Infected Patients for 24 weeks. 6th Conference on Retroviruses and Opportunistic Infections, January 31 - February 4
3	1995-96	<p>Robert Colgrove, Beth Israel Hospital, Boston, MA</p> <p>Title: Mathematical Modeling of HIV Drug Resistance</p> <p>Publication:</p> <ul style="list-style-type: none"> Colgrove, R., Japour, A. A Combinatorial Ledge: Reverse Transcriptase Fidelity, Total Body Viral Burden, and the Implications of Multiple-Drug HIV Therapy for the Evolution of Antiviral Resistance. <i>Antiviral Res</i> 41:45-56 Colgrove, R., Japour, A.J. Mathematical Modeling of Within-Patient Evolution of HIV-1 Antiretroviral Resistance as a Function of HIV Reverse Transcriptase Fidelity and Total-Body HIV Virion Burden Predicts Sharp Non-linear Superiority of Three-drug Over Two-drug Therapeutic Regimens. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 406 <p>Title: Maternal-Infant HIV Drug Resistance Transmission</p> <p>Publication:</p> <ul style="list-style-type: none"> Colgrove, R.C., Pitt, J., Chung, P.H., Welles, S.L., Japour, A.J. Selective Vertical Transmission of HIV-1 Antiretroviral Resistance Mutations. <i>AIDS</i> 12:2281-2288 Colgrove, R., Pitt, J., Japour, A., Welles, S. Evolutionary Hotspot around RT Codon 215 Evolves During Zidovudine Exposure. 6th Conference on Retroviruses and Opportunistic Infections, January 31 - February 4 Colgrove, R., Pitt, J., Chung, P., Welles, S., Japour, A.J., Harvard Medical School, Boston, Massachusetts, Columbia University, and University of Minnesota, Minneapolis, Minnesota. Selective Vertical Transmission of HIV-1 Zidovudine Resistance Mutations. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois
2	1995-96	<p>Jennifer Adelson-Mitty, Beth Israel Hospital, Boston, MA</p> <p>Title: HIV Immune Reconstitution Syndrome</p> <p>Publication:</p> <ul style="list-style-type: none"> Race, E., Adelson-Mitty, J., Barlam, T., Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI)

		in Patients with Advanced HIV-1 Disease. <i>Lancet</i> 351:252-255
1	1994-96	Elizabeth Race, Beth Israel Hospital, Boston, MA Title: HIV Immune Reconstitution Syndrome Publication: <ul style="list-style-type: none"> • Race, E., Adelson-Mitty, J., Barlam, T., Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1 Disease. <i>Lancet</i> 351:252-255 • Race, E., Reimann, K., Letvin, N. and Japour, A.J. Recurrence of Trimethoprim-Sulfamethoxazole TMP-SMX Hypersensitivity Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 535 • Race, E., Adelson-Mitty, J., Barlam, T., and Japour, A.J. Focal Inflammatory Lymphadenitis (FIL) and Fever Following Initiation of Protease Inhibitor (PRI) in Patients with Advanced HIV-1 Disease. 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC. 352

12. OTHER PROFESSIONAL ACTIVITIES AND PUBLIC SERVICE

SERVICE DETAILS		
Editorial Boards		
No	Date	Editorial Board
1	1995-96	Associate Editor, AIDS Clinical Care published by the Massachusetts Medical Society
Journal Reviews		
No	Date	Reviewing Duties: Journal
6	2012	Future Virology- <i>ad hoc</i>
5	2002-03	Clinical Infectious Diseases- <i>ad hoc</i>
4	1995-03	AIDS- <i>ad hoc</i>
3	1995-2003	Journal of Infectious Diseases- <i>ad hoc</i>
2	1994-98	Journal of Clinical Microbiology- <i>ad hoc</i>
1	1994-2003	Journal of AIDS- <i>ad hoc</i>
Grant Reviews		
No	Date	Agencies
1	1993-2010	<i>Ad hoc</i> Reviewer, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
Conference Committees-AIDS Clinical Trials Group (ACTG)		
No	Date	Conference Information
10	1996	Assay Development Committee, Virology Quality Assurance Program NIH-DAIDS
9	1994-96	NIH ACTG Adult Scientific Virology Committee, Core Member
8	1994-95	NIH ACTG Genotype Sequencing Swat Team, Core Member
7	1994-95	NIH ACTG HIV Resistance Screening Assay Swat Team, Chair
6	1994-95	Assay Development Committee, NIH AIDS Clinical Trial Group; Vice Chair
5	1993-96	Beth Israel Hospital Clinical Research Center Scientific Advisory Committee

4	1993-95	NIH ACTG Primary Infection Committee Phase II/III Working Group
3	1993-94	NIH ACTG MT-2 Swat Team, Chair
2	1990-95	NIH ACTG Virology Committee
1	1990-93	NIH ACTG HIV Resistance Working Group, Core Member
Others		
No	Date	National Activities
23	2014	Hepatology Speaker's Bureau, AbbVie, North Chicago, IL
22	2014	Hepatitis C Speaker's Advisory Board, Bristol-Myers Squibb, Plainsboro, NJ
21	2014	HIV Clinical Advisory Board, Bristol-Myers Squibb, Plainsboro, NJ
20	2014	Hepatitis Clinical Advisory Board, Gilead Pharmaceuticals, Foster City, CA
19	2013- Present	Hepatitis C Speaker's Bureau, Janssen Pharmaceutical Company
18	2013	Hepatitis C Speaker's Advisory Board, Boehringer Ingelheim GmbH Pharmaceuticals, Ridgefield, CT
17	2011- Present	Hepatitis C Speaker's Advisory Board-USA, Merck & Company, Blue Bell, PA
16	2011-2013	Health Advisory Board, City of Miami Beach
15	2011- Present	Scientific Advisory Board, ImmunoGenetix, Inc., Lenexa, KS
14	2009- Present	American Bar Association, AIDS Coordinating Committee, Health Care Advisory, Washington, D.C.
13	2010	Homeless Committee, City of Miami Beach, Miami Beach, FL
12	2009-10	Republican Primary Candidate, State of Florida House of Representatives, District 107
11	2007-10	Cultural Arts Council, City of Miami Beach, Miami Beach, FL
10	2006	Community Development Advisory Council, City of Miami Beach, Miami Beach, FL
9	2004-11	Florida Medical Association, Tallahassee, FL
8	2006-08	Miami Beach Bar Association, Miami Beach, FL
7	2006-07	Miami Beach Chamber of Commerce, Miami Beach, FL
6	2004-06	Scientific Advisory Board, Sequoia Pharmaceuticals, Inc., Gaithersburg, MD
5	2004-06	Fine Arts Board, City of Miami Beach, Miami Beach, FL
4	2004-05	Scientific Advisory Board, PPD Inc. Government Group, Wilmington, NC
3	2003-07	Miami Beach Latin Chamber of Commerce, Miami Beach, FL
2	1999-02	Board of Directors, Open Hand Chicago, Chicago, IL
1	1989-96	Blackstone - Franklin Square Neighborhood Association, Boston, MA
University Service		
Year	No	Committees
1995-96	2	Scientific Director, Harvard-Thorndike General Clinical Research Center Molecular Core Laboratory
1995	1	Beth Israel Hospital- Harvard Medical School, HIV Endowment Fund